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Abstract 
 
Respiratory syncytial virus is the most frequent cause of hospitalization for 
viral respiratory infections in infants and young children worldwide. It also 
severely affects immunocompromised adults and the elderly, however, 
despite decades of efforts, there is no proven effective treatment for RSV 
infection and attempts at vaccine development have been hampered by 
several major obstacles.  
 
A large amount of research has established the potent antibacterial activity of 
honey, but its activity against viral species has been the subject of only a 
small number of studies. These were with viruses which cause localised 
infections in which honey could be used topically. Recent studies 
demonstrating the safety of intrapulmonary administration of honey in 
sheep and humans raised the possibility of using honey to treat respiratory 
infections.  The aim of this study, therefore, was to extend the knowledge 
obtained from previous studies of honey’s antiviral activity to its action 
against RSV. 
 
A variety of tests using cell culture were developed to evaluate the 
susceptibility of RSV to honey.  Each test monitored and scored the 
development of morphological changes to the cells caused by RSV infection 
to determine whether the honey had any inhibitory effect on these changes.  
These included tests for: inhibition, where honey was used to treat infected 
cells; protection, in which the cells were treated with honey prior to 
infection; neutralisation, in which the virus was directly exposed to the 
honey for a defined period before being used to inoculate the cells.  
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Pre-treatment of the cells had no effect on the consequent development of 
cytopathic effect, while the inhibition and neutralisation experiments 
showed a significant inhibitory effect on the progression of infection, 
suggesting a direct effect on the virus rather than on the cells, however, 
further studies are required to confirm this. 
 
A wide range of honey types were tested for their inhibitory and neutralising 
capabilities against RSV and the results suggested that the antiviral activity 
may be characteristic of more than one type of honey. The activity observed 
did vary, however, with some types of honey causing greater inhibition of 
RSV than others. 
 
Enzyme-linked immunosorbent assays were also used to quantitatively 
measure the number of viral antigens in honey-treated and untreated cells. 
The results confirmed that treatment with honey had caused inhibition of 
viral replication, there being very little virus detected in honey-treated cells 
compared with untreated cells infected with RSV. Experiments using 
quantitative PCR also demonstrated the inhibitory effect of honey on RSV at 
the transcription level, with significant differences in the mRNA copy 
numbers of two out of the three viral genes examined. 
 
Attempts at isolating the antiviral component in honey demonstrated that 
the sugar was not responsible for the inhibition of RSV, but that 
methylglyoxal may play a part in the greater potency of Manuka honeys 
against RSV.  
 
It is concluded from the findings in this study that honey may possibly be an 
effective antiviral treatment for the therapy of respiratory viral infections, 
and provides justification for future in vitro studies and clinical trials.
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Chapter One  
                               Introduction 
 
Over the last few decades, there have been many investigations looking at 
the antibacterial properties of honey, but only a small number have 
investigated its antiviral properties. These few have demonstrated the 
antiviral effects of honey against a number of viruses for which current 
treatment may not be very effective or may be known to cause adverse side 
effects. It was thus desirable that the activity of honey be tested against other 
viral pathogens, to determine its potential as a treatment and to expand the 
field of knowledge in this area of study. One such pathogen is respiratory 
syncytial virus, a respiratory virus causing millions of hospitalisations and 
hundreds of thousands of deaths worldwide annually, and for which there is 
currently no vaccine or effective treatment. Ribavirin is sometimes used in 
hospitals, but only in the most severe cases, as studies have failed to 
establish its efficacy in infected individuals.  A study demonstrating the 
safety of intrapulmonary administration of honey into sheep and humans 
indicated that using it as a therapy for RSV infection was a feasible prospect. 
 
The second chapter of this thesis provides background information on 
respiratory syncytial virus and the history and uses of honey. Other early 
chapters describe experiments performed which aimed to observe the 
different aspects of the activity of honey against RSV including its inhibitory, 
protective and neutralising properties. These experiments involved utilising 
cell culture to perform a number of investigations which examined the 
effects of honey on the virus, and a number of molecular techniques were 
used to confirm the effects observed as changes in cell morphology. 
  
 
2 
 
Differences in the antiviral activity of different honey types were also 
investigated.  
 
 The later chapters of this thesis describe work in which it sought to 
determine the mechanism of action of honey, and experiments were 
performed to investigate the effects of honey on the replication kinetics of 
RSV. This was done by comparing the amount of transcripts for viral genes 
detected in RSV-infected samples which had been incubated with or without 
honey. Several experiments were also conducted with the aim of isolating 
the component in honey responsible for the observed activity. These 
included tests with the sugar, hydrogen peroxide and methylglyoxal 
components of honey.  
 
The final chapter of this thesis discusses the relevance and importance of the 
findings from the previous chapters, and provides suggestions for future 
investigations in this area of study. 
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Chapter Two  
   Literature Review 
 
2.1 Respiratory Syncytial Virus 
2.1.1 Introduction and history 
Respiratory syncytial virus (RSV) was first isolated in 1956 from a laboratory 
chimpanzee with an illness resembling the common cold and later identified 
to be a human pathogen. RSV is a member of the subfamily Pneumovirinae in 
the family Paramyxoviridae, order Mononegavirales (Cowton et al., 2006). 
Worldwide, it is implicated in the majority of lower respiratory tract 
infections for which newborns require treatment and often hospitalization 
(Hall et al., 1976). RSV disease manifestations include rhinitis, bronchiolitis 
and pneumonia as well as being a likely contributor to otitis media in older 
children (Ruuskanen et al., 1989). RSV can also cause significant disease in 
the elderly and is associated with higher mortality rates than influenza in 
non-pandemic years (Falsey et al., 1995). Even though maternal antibodies 
are usually present, disease caused by RSV is specifically severe in children 
between 1 and 3 months old (Kim et al., 1973). Reinfection is also common in 
all age groups (Murphy et al., 1994). Despite the importance of RSV being 
recognised for over 45 years, a licensed vaccine is still currently unavailable 
(Maggon & Barik, 2004).  Several issues have been faced during its 
development, such as adverse reactions in the form of “vaccine-enhanced 
disease”, of which will be discussed in a later section in this thesis.  
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2.1.2 Virion structure and viral proteins 
RSV is an enveloped virus with a single-stranded, negative-sense, non-
segmented RNA genome composed of approximately 15 222 nucleotides and 
10 genes which encode 11 proteins (Falsey & Walsh, 2000) as exemplified in 
Figure 2.1. It ranges in size range from 120 to 300 nm and isolates can be 
segregated into two subgroups, A and B. In the RSV particle, the genome is 
contained within the helical viral protein N to form the nucleocapsid, 
packaged in a lipoprotein envelope acquired from the host cell plasma 
membrane during budding. The outer surface of the envelope contains a 
fringe of surface projections of around 12 nm (Collins, 2008). Human RSV 
lacks a hemagglutinin or a neuraminidase (Collins, 2008). The genome 
encodes three transmembrane surface proteins (F, G, SH), a matrix protein 
(M), the nucleocapsid protein (N), nucleocapsid-associated proteins (M2-1, P, 
L), a M2-2 protein, and two non-structural proteins (NS1 and NS2) (Maggon 
& Barik, 2004).   
 
Figure 2.1 The human RSV RNA genome illustrated 3' to 5' as published by 
Leaman (2005) 
 
 
The G protein is a type II transmembrane protein with an N-terminal 
transmembrane domain. It is also found in a smaller secreted form that lacks 
the transmembrane region and is produced by a translation initiation site at 
a second AUG in the mRNA, followed by proteolytic trimming (Roberts et 
al., 1994). The G protein is responsible for attachment of the virus particles to 
the host cell, although this function can also be provided by the F protein 
(Levine et al., 1987; Karron et al., 1997a). The F protein promotes entry of the 
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virus particles into the host cell by fusion with the target cell plasma 
membrane, as well as the spreading of virus between cells by cell-to-cell 
fusion (Walsh & Hruska, 1983). The antigenic diversity in human RSV is 
associated with a high degree of amino acid heterogeneity in the G protein 
sequence with only 53% identity in sequences between the two subgroups 
(Johnson et al., 1987). Within subgroups, the G protein is also highly variable, 
with 20% amino acid variability between subgroup A strains (Cane & 
Pringle, 1995) and 9 % variability between subgroup B strains (Sullender et 
al., 1990).  
 
The SH protein of RSV is a type II transmembrane protein containing 64 
(subgroup A) or 65 (subgroup B) amino acid residues (Collins & Wertz, 1985; 
Olmsted & Collins, 1989; Collins et al., 1990; Collins & Mottet, 1993). Some 
studies have suggested that the RSV SH protein may have a role in viral 
fusion (Heminway et al., 1994; Techaarpornkul et al., 2001) or in changing 
membrane permeability. However, it has been shown that RSV lacking the 
SH gene is viable, causes syncytium formation and grows just as well as the 
wild-type virus (Bukreyev et al., 1997; Karron et al., 1997a; Webster et al., 
2002), indicating that the SH protein is not necessary for virus entry into host 
cells or syncytium formation. Parainfluenza virus 5, a prototypical 
paramyxovirus, also encodes an SH protein which inhibits tumor necrosis 
factor alpha (TNF-α) signalling. In a study by Fuentes et al. (2007), 
recombinant PIV5 viruses without their own SH but containing RSV SH  in 
its place (from A2 or B1 strains), and RSV lacking its own SH were generated 
and analyzed. The results indicate that the SH protein of RSV has a function 
similar to that of PIV5 SH and that it can inhibit TNF-α signalling.  
 
The matrix protein M is an envelope-associated protein and is required for 
viral assembly. The nucleoprotein N, phosphoprotein P and large 
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polymerase fragment L are found in the nucleocapsid, and together with the 
co-factors M2-1 and M2-2 form the RNA dependent RNA polymerase 
complex (Yu et al., 1995). M2-1 and M2-2 are both involved in viral RNA 
synthesis, but only M2-1 is essential (Fearns & Collins, 1999). NS1 and NS2 
are non-structural viral products that accumulate in infected cells but are 
present only in trace amounts in the mature virion (Olmsted & Collins, 1989). 
They also antagonise the α/β IFN response in a species-specific manner 
(Schlender et al., 2000; Bossert & Conzelmann, 2002; Bossert et al., 2003).  
      
2.1.3 Antigens and antigenic subgroups 
Human RSV has a single serotype. However, isolates can be segregated into 
two serological subgroups, A and B (Kesson, 2007). Although the sequences 
of all 11 viral proteins differ to one extent or another between these two 
groups, the G protein shows the greatest divergence between prototype A 
and B viruses (Sugawara et al., 2002; Teng & Collins, 2002). Epitopes in F 
tend to be conserved while those for G are not, such that antigenic 
relatedness between the two subgroups is greater than 50% for the F protein 
compared to only 5% or less for the G protein. At the amino acid level, F is 
89% identical between subgroups while G is the most divergent of the 
proteins and is only 53% identical. Other proteins range from 76% (SH) to 
96% (N) identical. Thus, the two antigenic subgroups have substantial 
differences throughout the genome and represent two divergent lines of 
evolution. In a two-year window following infection, there was a 64% 
reduction in the incidence of infection by the same subgroup versus a 16% 
reduction against the heterologous subgroup. In epidemics, there is typically 
an alternating pattern with a 1-2 year interval with regard to the 
predominant subgroup (Collins & Graham, 2008). Several investigations 
have reviewed the regional and global epidemiology of these strains (Cane et 
al., 1994; Sullender, 2000; Crotty & Andino, 2002; Hacking & Hull, 2002). The 
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impact of antigenic diversity on RSV epidemiology is not yet completely 
understood, but may partly explain the susceptibility to reinfection 
throughout life and also the yearly variation observed in the severity of 
epidemics within communities (Cane et al., 1994; Sullender, 2000; Crotty & 
Andino, 2002).  
 
2.1.4 Epidemiology and clinical presentation 
Human RSV is recognised as an important pathogen in young children, 
immunocompromised adults and in the elderly. It is estimated by the World 
Health Organization (2010) to cause around 64 million infections and 160 000 
deaths annually in the pediatric population. It infects up to 65% of babies in 
their first year of life and essentially all babies within their first two years of 
life (Maggon & Barik, 2004). Hospitalization rates in developed countries are 
approximately one in every 100 to 200 infections. RSV is responsible for the 
admission of 0.1% to 2% of babies under the age of 1 to hospital each year for 
bronchiolitis and among these, mechanical ventilation is needed in 2% to 5% 
(Leader & Kohhase, 2002). RSV infection also increases the risk for severe 
illness in children with underlying problems such as bronchopulmonary 
dysplasia, chronic lung disease, congenital heart disease and babies born 
prematurely (Cane, 2001; Maggon & Barik, 2004). 
 
Primary infantile RSV infection typically presents as a winter upper 
respiratory tract infection followed by mild lower respiratory tract 
symptoms in about 40% of cases (Openshaw & Tregoning, 2005), however, 
there have been a number of studies on RSV in developing countries such as 
South Africa (Madhi et al., 2003), Indonesia (Djelantik et al., 2003), and the 
Gambia (Weber et al., 2002), where RSV infections are usually seasonal and 
not necessarily most frequent at the coldest time of year (Stensballe et al., 
2003). High sibling number remains an important risk factor in all settings, 
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however, some risk factors play a more important role in developing 
countries and include, for example, the presence or absence of a flushing 
toilet and exposure to cooking fires (Weber et al., 1999). Young children aged 
8 to 30 weeks tend to experience more severe illness, however, RSV 
infections usually pass in less than a week (Openshaw & Tregoning, 2005). 
Very few previously healthy children suffer life-threatening infections, and 
deaths are mostly confined to immunocompomised individuals and those 
who have pre-existing cardiorespiratory disease (Ruuskanen & Ogra, 1993; 
Henrickson et al., 2004).  
 
Although more well-recognized as a pediatric pathogen, RSV is also known 
to cause life-threatening pulmonary disease in immunocompromised adults 
such as bone marrow transplant recipients and sufferers of cystic fibrosis. 
The elderly are also at high risk of pulmonary disease: RSV attack rates in 
nursing homes in the USA are approximately 5% - 10% per year with a 2% - 
8% case fatality rate, amounting to approximately 10 000 deaths per year 
among persons  over 64 years of age (Falsey & Walsh, 2005). RSV has a major 
impact on humans, claiming around 3 to 5 million live annually (Cane, 2001).  
 
In experimental infections, RSV has an incubation period of 4 to 5 days. 
Virus is typically shed for 7 to 12 days, although sometimes shedding is 
longer and may continue after recovery. Most primary infections are 
symptomatic, with upper respiratory tract disease and sometimes, a fever. 
Twenty-five to forty percent of infections progress to the lower respiratory 
tract with the primary manifestations of serious disease being pneumonia or 
bronchiolitis (Collins, 2008). Symptoms include profuse rhinorrhea, 
coughing, fever, wheezing and middle-ear disease and seriously ill infants 
may experience severe coughing, wheezing, rapid respiration and 
hypoxemia, requiring the administration of humidified oxygen. RSV causes 
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yearly epidemics centered in the winter months in temperate climates, or in 
the rainy season in the tropics, though there may be some local variations to 
this pattern (Collins, 2008). 
 
2.1.5 Pathogenesis 
Inoculation occurs at the nasal or ocular mucosa via direct contact with 
secretions or infected fomites (Hall & Douglas, 1981; Hall et al., 1981). Both 
droplet and contact transmissions are the main methods of spread, and thus 
hand washing, droplet isolation, and the use of personal protective 
equipment are all important in reducing the spread of RSV.  
 
The virus first infects the epithelial cells of the upper respiratory tract and 
primarily replicates in the epithelial cells that line the lumen of the 
respiratory tract, as well as macrophages and dendritic cells. Infection then 
spreads to the epithelium of the bronchioles and from the bronchioles, the 
virus can then extend to the type 1 and 2 alveolar pneumocytes (Aherne et 
al., 1970; Johnson et al., 2007). RSV has a direct cytopathic effect on cells in the 
lung epithelium, leading to loss of specialized functions such as cilial 
motility and sometimes to epithelial destruction (Aherne et al., 1970). A 
peribronchiolar mononuclear cell infiltrate also forms, accompanied by 
submucosal edema and mucus secretion. The inflammation leads to 
bronchiolar obstruction with patchy atelectasis and compensatory 
emphysema (Gardner et al., 1970). Mucus, inflammatory cells and debris 
from dead infected cells often accumulate in the airways and cause 
obstruction, which is of special concern in infants due to the small diameter 
of their airways (Collins, 2008). RSV pathogenesis in vitro is normally 
characterised by syncytium formation which is seldom seen in vivo. 
However, this varies considerably from one strain to another (Shigeta et al., 
1968).  
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Human RSV has been shown to have an incubation period of 4 to 5 days in 
experimental infections (Collins, 2008). Virus is typically shed for 7 to 12 
days, although sometimes shedding is longer and may continue after 
recovery. Most primary infections are symptomatic, with upper respiratory 
tract disease and sometimes, a fever. Symptoms may include rhinorrhea, 
coughing, fever, wheezing and middle-ear disease and seriously ill infants 
may experience severe coughing, wheezing, rapid respiration and 
hypoxemia, requiring the administration of humidified oxygen (Collins, 
2008). Twenty-five to forty percent of infections progress to the lower 
respiratory tract with the primary manifestations of serious disease being 
pneumonia or bronchiolitis (Collins, 2008). A study has shown that children 
who experienced severe RSV bronchiolitis during infancy had a significantly 
higher rate of asthma than age and sex-matched controls (Sigurs, 2001). In 
this same cohort studied at 13 years of age, asthma had been diagnosed in 
37% of the RSV bronchiolitics and only 5.4% of the control group (Sigurs et 
al., 2005). The RSV group had a significantly higher occurrence of symptoms 
over the previous 12 months than among the control subjects, 43% versus 8% 
for asthma/recurrent wheezing and 39% versus 15% for allergic 
rhinoconjunctivitis. Sensitization to common inhaled allergens was also more 
frequent in the RSV group, judged by skin prick tests (50% versus 28%; p = 
0.022), or by serum IgE antibodies (45% versus 26%; p = 0.038). The RSV 
group also showed mild airway obstruction both at rest and after 
bronchodilation, and had slightly more reactive airways compared with their 
control counterparts. 
 
2.1.6 Immune response 
RSV is an acute infection that is typically cleared completely by host 
immunity, although shedding may sometimes persist for weeks. Studies in 
experimental animals and in the clinic have indicated that immunity to the 
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virus is mediated via humoral and cellular effectors, including serum 
antibody, secretory antibody and major histocompatibility complex class I 
and class II-restricted cytotoxic T lymphocytes (Maggon & Barik, 2004). 
These same effectors are also thought to confer protection against reinfection. 
Protection conferred by cytotoxic T lymphocytes appears to diminish within 
several weeks or months and is more important in the short term. Virus-
neutralizing secretory IgA antibodies are effective in restricting infection, 
however this response is also short-lived. Virus-neutralizing serum 
antibodies are thought to provide longer lasting protection, however, due to 
the poor method by which they gain access to the respiratory lumen, this 
protection is not thought to be very efficient (Maggon & Barik, 2004).  
 
The innate immune response is the body’s first line of defense against 
infectious diseases. A specific group of proteins that comprise the Toll or 
Toll-like family of receptors perform this role in vertebrate and invertebrate 
organisms. One study demonstrated that the F glycoprotein of RSV activated 
TLR4, most likely through interaction with the surface molecule CD14+, 
which is expressed primarily on monocytes (Kurt-Jones et al., 2000). In 
human monocytes stimulated in vitro with F protein purified from the RSV 
A2 strain, TLR4 was involved in the release of interleukin (IL)-6, IL-8 and IL-
1b (Kurt-Jones et al., 2000). In addition, Haynes et al. (2001) report that RSV-
challenged mice deficient in TLR4 experienced a decrease in CD14+ and NK 
cell trafficking to the lungs, impaired NK cell activity, reduced IL-12 
expression, and decreased ability to clear virus compared to mice expressing 
TLR4.  However, RSV-specific cytotoxic T lymphocyte responses were 
similar in both groups in vitro (Haynes et al., 2001), suggesting that 
mechanisms of viral clearance other than MHC class I perforin-mediated 
lysis of infected cells may be important in RSV infection control.  
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RSV infection exerts its effects on the TLR4/innate immunity pathway by 
triggering NF-κB nuclear translocation followed by the binding and 
activation of target genes (Haeberle et al., 2002). Nuclear extracts from the 
lungs of C3H/HeJ mice, lacking a functional TLR4 signaling pathway, and 
control mice were examined for NF-κB binding activity and it was found 
that early after inoculation, neither live nor UV-inactivated RSV induced 
significant nuclear translocation of NF-κB in TLR4-deficient mice. 
Conversely, nuclear translocation of NF-κB subunits RelA, p50 and c-Rel was 
detected in control mice 30 minutes after RSV infection and was reduced by 
the depletion of alveolar macrophages. Subsequently, late NF-κB binding 
was detected in TLR4-sufficient and -deficient mice at 24 hours only after 
live RSV inoculation, and was not affected by depletion of alveolar 
macrophages (Haeberle et al., 2002). These findings suggest that there may 
be at least two distinct RSV-inducible NF-κB responses in the lungs of RSV-
infected mice: an early response that is TLR4- and AM-dependent and does 
not require virus replication and a later TLR4- and AM-independent 
response, probably affecting respiratory epithelial cells and requiring RSV 
replication (Haeberle et al., 2002). Considerable evidence suggests that innate 
immune inflammation plays a role in RSV pathogenesis, however, the role of 
the innate immune response during RSV infection requires further study.  
 
The immune response during the first months of life  has been shown to be 
reduced due to immunologic immaturity as well as the immunosuppressive 
effects of the maternal antibodies on humoral responses (Collins, 2008). This 
may facilitate reinfection in early life. The Th2-biased nature of immune 
responses in early infancy has also been speculated to contribute to human 
RSV disease and reduced immune responses.  The tropism of RSV to the 
superficial epithelium may also be reducing its exposure to immune effectors 
and may also be providing reduced immune stimulation (Collins, 2008). The 
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lack of protection may also be explained by group specificity, since children 
with primary RSV infection develop a neutralising antibody of greater 
frequency and magnitude to the infecting strain than to a heterologous RSV 
strain (Maggon & Barik, 2004).    
 
2.1.7 Vaccines 
Numerous obstacles have prevented the development of an effective RSV 
vaccine. In the 1960s, a formalin inactivated RSV vaccine was studied in 
human infants for the first time. Not only did it fail to protect against 
subsequent wild-type RSV disease, it also induced an exaggerated clinical 
response, causing as many as 80% of vaccinated children to be hospitalized 
and two infant deaths (Chin et al., 1969; Fulginiti et al., 1969; Kapikian et al., 
1969; Kim et al., 1969). Infiltration of excess eosinophils into the peribronchial 
spaces and deposits of non-protective antibodies complexed with virus in 
affected tissue were blamed for the vaccine-enhanced disease (Chin et al., 
1969; Fulginiti et al., 1969; Kapikian et al., 1969; Kim et al., 1969; Murphy et al., 
1986; Polack et al., 2002). 
 
 As evidenced by natural reinfection, it is thought to be unlikely that a single 
vaccination will impart complete protection against RSV disease. The goal 
for a successful vaccine should therefore be to prevent serious RSV 
associated lower respiratory tract infections in those individuals at risk 
(Collins & Murphy, 2005). RSV vaccine development is currently focused on 
live, attenuated strains for intranasal administration. This strategy 
accomplishes several goals: it induces local mucosal and systemic immunity, 
the intranasal route partially escapes the suppressive effects of maternal 
serum antibodies (Crowe et al., 1995), and, compared with inactivated 
vaccines, live intranasal vaccines are more immunogenic and provide 
broader protection (Johnson et al., 1986). 
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The balance between attenuation and immunogenicity is critical in vaccine 
development. Live vaccine candidates have been developed using serial 
passages at decreasing temperatures (cold passage) and chemical 
mutagenesis to produce temperature sensitive mutants. These viruses will 
replicate at the low temperatures of the upper respiratory tract but not at the 
high temperatures of the lower respiratory tract (Collins & Murphy, 2005). 
Initial vaccine candidates developed using these attenuation methods were 
found to be either too reactive or overattenuated, and mutations were often 
unstable (Karron et al., 1997b; Wright et al., 2000). The latest strategy to 
effectively attenuate RSV is through reverse genetics (Collins & Murphy, 
2005), which involves producing infectious virus from cloned 
complementary DNAs in cell culture and introducing targeted mutations to 
achieve more precise levels of attenuation while maintaining sufficient 
immunogenicity (Collins et al., 1995; Firestone et al., 1996). 
 
Recombinant RSV A2 cp248/404/1030/ΔSH is a recombinant temperature-
sensitive RSV with a deletion of the SH gene (Karron et al., 2005). The SH 
protein has been shown to decrease TH1 responses, inhibiting the host 
antiviral response as a result. A virus lacking the SH protein would therefore 
impart greater immunogenicity (Tripp et al., 1999). It is the first vaccine 
candidate to be sufficiently attenuated for young infants. A phase 1/2a study 
is currently recruiting healthy children between the ages of 1 and 24 months 
to evaluate immunogenicity, viral shedding, safety, and tolerability 
(Clinicaltrials.gov, 2010). Other vaccine candidates under development using 
these attenuation strategies include recombinant RSV A2 cpts248/404/ΔNS2 
and recombinant RSV A2 cpts530/1009ΔNS2, which include a deletion in the 
NS genes. The NS protein decreases type I interferon signalling, thus 
inhibiting host response (Ramaswamy et al., 2006). Similar to SH deletions, 
virus lacking the NS proteins will be more immunogenic. There is still 
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concern regarding the genetic stability of these vaccine candidates, however, 
highly attenuating gene deletion vaccines have been developed to address 
this. These include ΔNS1, ΔM2–2, and ΔM2– 2NS2 which all maintained a 
high level of immunogenicity when evaluated in chimpanzees (Ramaswamy 
et al., 2006). They were also shown to induce protection after wild-type RSV 
challenge. Further evaluation in humans is needed (Teng et al., 2000; Cheng 
et al., 2001; Jin et al., 2003). 
 
An alternative method for overcoming genetic instability while maintaining 
immunogenicity is through the delivery of RSV proteins using viruses with 
greater growth and stability (Collins & Murphy, 2005). The vector vaccine 
candidate recombinant bovine/human parainfluenza virus type 3 (PIV3)/ 
RSV F2 delivers RSV F using a bovine/human chimeric parainfluenza type 3 
genome. This candidate was shown to protect monkeys against challenge 
with wild-type RSV and generated high titers of RSV and human PIV3-
neutralizing antibodies (Tang et al., 2004). Safety was demonstrated in a 
phase 1 study of RSV-seropositive adults, however, further studies are 
needed to determine its safety in children (Tang et al., 2008). Other viruses 
engineered to express RSV F and/or G glycoproteins include the Newcastle 
disease (Martinez-Sobrido et al., 2006) and Sendai viruses (Takimoto et al., 
2004), both of which have demonstrated protection in rodent models.  
 
Purified RSV F, G, and M proteins have been evaluated for their potential to 
induce neutralizing and protective antibodies. The following subunit 
vaccines have advanced to clinical trials: (1) Three RSV F subunit vaccines 
(purified F protein 1–3) (Wathen et al., 1991; Simoesa et al., 2001); (2) a 
combined subunit vaccine containing F, G, and M proteins (Sanofi Pasteur) 
(Falsey et al., 2008); and (3) BBG2Na, a G peptide conjugated to streptococcal 
protein G (Power et al., 2001). Only modest rises in antibody titers have been 
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observed in seropositive populations and their safety and efficacy in RSV-
naive infants and young children is yet to be determined. Drawbacks to this 
vaccine approach include poor immunogenicity, immunosuppressive effects 
of maternally acquired antibodies, and potential for vaccine-enhanced 
disease (Empey et al., 2010). 
 
2.1.8 Potential therapeutics 
Inhibitors of RSV that have recently been evaluated for efficacy fall into six 
groups classified according to their modes of action: those that inhibit 
attachment/fusion, oligonucleotides that target viral RNA, those that target 
the N-protein, those that inhibit some function of the virus RNA-dependant 
RNA polymerase, those that inhibit inosine monophosphate dehydrogenase 
(IMPDH), and also antibody preparations which interfere with pathogen 
binding, and facilitate opsonization, neutralization, and clearance of viruses. 
Currently, only ribavirin – an inosine monophosphate dehydrogenase 
inhibitor – is being used in hospitals. It is only used in the most severe cases 
as studies have been unable to prove its efficacy. 
 
2.1.8.1 Attachment/fusion inhibitors 
Fusion is a critical step in the life-cycle of RSV and the inhibition of this step 
has been shown to lead to a reduction in viral load and syncytia formation 
(Colman & Lawrence, 2003; Bonfanti & Roymans, 2009). The F and G 
proteins are involved in virus attachment and fusion, although it has been 
shown that the F protein alone is sufficient to promote attachment to cells, 
subsequently leading to a productive viral infection (Karron et al., 1997a). 
The G protein may simply enhance attachment to a target cell, but the F 
protein is thought to bind to a specific receptor (Techaarpornkul et al., 2001). 
On viral coalescence with target cell membranes, the F glycoprotein 
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undergoes a conformational change exposing hydrophobic pockets or 
epitopes (Lawless-Delmedico et al., 2000). As a result, binding of these 
exposed targets by RSV fusion inhibitors prevents viral entry in the host cell 
(Zhao et al., 2000). Several small-molecule fusion inhibitors have already 
been screened, each targeting a slightly different epitope within the F 
glycoprotein, however, attempts at development of these compounds have 
met an extremely high rate of failure, and only a few are still viable 
candidates for licensing. None are currently in advanced stages of clinical 
trials. 
 
a) BTA9881  
BTA9881 is a prototype compound from a new class of RSV fusion inhibitors 
(imidazoisoindole derivatives) belonging to Biota (AstraZeneca). The 
compound had very high oral bioavailability and favorable 
pharmacokinetics in phase I clinical trials, but failed to develop an acceptable 
safety profile (Luttick et al., 2007). Rights to the compound have since been 
returned by AstraZeneca to Biota, who will attempt to develop more 
attractive derivatives (Welliver, 2010). 
 
b) TMC-353121 
TMC-353121, a compound under development by Tibotec (Johnson & 
Johnson), has previously been shown to have picomolar activity against 
various RSV strains when given to cotton rats by intravenous, oral and 
aerosol routes. This compound is a morpholinopropylaminobenzimidazole 
derivative of JNJ-2408068 (a benzimidazole with potent anti-RSV activity), 
with the revision of the compound prolonging its halflife (Bonfanti et al., 
2008). The derivative inhibits both virus–cell fusion and cell–cell fusion 
specifically for RSV, with no activity against other Paramyxoviridae (Andries 
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et al., 2003). The drug enters the lung and is active at 10 nmol/l 
concentrations, with very low levels outside the lung (Wyde et al., 2003). The 
drug also inhibits the release of IL-6, IL-8 and RANTES from RSV-infected 
A549 cells (Andries et al., 2003). 
 
c)  VP-14637 
VP-14637 was one of the first fusion inhibitors to progress to Phase I clinical 
trials. It is a triphenolic compound which is thought to bind into the small 
hydrophobic cavity in the inner core of the F-protein, either preventing early 
transient Z conformation changes in the fusion process or by preventing 
formation of six-helix fusion core as the heptad repeats interact (Douglas et 
al., 2005). VP-14637 is a broad-spectrum inhibitor of RSV strains, inhibiting 
the virus in vitro at concentrations of 2 nmol/l or less (Douglas et al., 2005; 
Wyde et al., 2005). In cotton rats, treatment by small droplet aerosol for 60 
minutes significantly reduced mean lung virus titers (Wyde et al., 2005). VP-
14637 was in phase I trials prior to a decision by ViroPharma to discontinue 
its development, mainly due to strategic reasons and developmental costs 
(Welliver, 2010). 
 
d)  BMS-433771 
Benzotriazole benzimidazoles represent another class of inhibitors that 
prevent fusion of RSV to host cell membranes. In particular, BMS-433771 (1-
cyclopropyl-1,3-dihydro-3-[[1-(3-hydroxypropyl)-1H-benzimidazol-2-
yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one), an azabenzimidazolone 
derivative, targets the hydrophobic pocket within the trimer of hairpins of 
the F-1 protein, a class I fusion protein (Cianci et al., 2004b). It is thought to 
interfere with the normal association of the N and C-terminal heptad repeats 
found within the binding pocket that occur as part of the fusion process 
   
 
19 
 
(Cianci et al., 2005). BMS-433771 is active against multiple RSV strains, with a 
50% inhibitory concentration of 20nM (Cianci et al., 2004b). In a T cell-
deficient BALB/c mouse model, the orally active compound also significantly 
reduced virus titers in the lungs and the compound was well tolerated 
(Cianci et al., 2004c), however, it was found to be somewhat less inhibitory to 
lung virus replication in cotton rats (Cianci et al., 2004a). It had progressed to 
Phase I/II clinical trials before being discontinued (Empey et al., 2010). 
 
e) RFI-641 
RFI-641 is a biphenyl triazine anionic compound that is an analog of CL-
309623, a previously identified dendrimer-like stilbene inhibitor with anti-
RSV activity (Gazumyan et al., 2000). Like its parent compound, RFI-641 
inhibits RSV fusion mediated by the F protein by directly interacting with 
that protein (Razinkov et al., 2002). The compound inhibited both A and B 
strains of RSV with EC50 values in the 20 nmol/l range. It was also found to be 
relatively non-toxic (Douglas, 2004). The compound has been evaluated 
extensively in small animal models (Huntley et al., 2002), and in African 
green monkeys (Weiss et al., 2003). In the mouse, RFI-641 at 1.3 mg/kg 
delivered intranasally 2 hours prior to virus exposure resulted in the 
reduction of lung virus titers by 1.5 log10 plaque-forming units. Using a 
similar prophylactic dosing regimen in cotton rats, doses up to 10 mg/kg 
appeared to reduce lung virus titers by >3 log10. RFI-641 prophylactically 
dosed at 6 mg/kg also appeared to reduce nasal virus titers by >3.4 log10 over 
a period of ten days in the primate. Using intranasal administration, lung 
virus titers were only substantially reduced after a two hour exposure to the 
compound (Weiss et al., 2003). Nasal virus titers were also significantly 
reduced when the compound was given 24 hours after virus exposure with 
daily doses thereafter (Huntley et al., 2002). RFI-641 reached Phase II clinical 
trials in 2000 to 2001, but has since been discontinued (Empey et al., 2010). 
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f) MBX 300 (NMSO-3) 
MBX 300 is a compound which targets the G protein and seemingly targets 
the attachment phase. It is RSV-specific (Kimura et al., 2000) with EC50 values 
of 0.2 to 0.3 μmol/l (Douglas, 2004). Lung virus titers were significantly 
reduced  in cotton rats when the compound was administered 
intraperitoneally at 100 mg/kg/day, 3 days post-virus exposure (Douglas, 
2004). According to Microbiotix, MBX 300 has undergone preliminary 
toxicology studies, including testing in Cynomolgus monkeys and has 
specific and potent oral anti-RSV activity as well as an excellent safety profile 
(Douglas, 2004; Sidwell & Barnard, 2006; Empey et al., 2010). It is still 
currently undergoing preclinical tests. 
 
2.1.8.2 Oligonucleotides that target viral RNA (antisense/siRNA) 
Much has been reviewed regarding the theory (Maggon & Barik, 2004), 
approaches used (Cramer, 2005), and attempts to develop antisense 
oligonucleotides (Leaman, 2005) as therapies for RSV disease. These attempts 
have included antisense phosphorothioate oligodeoxyribonucleotides (ODN) 
(Jairath et al., 1997), short interfering double-stranded RNA molecules 
(siRNA) (Bitko et al., 2005), and 2–5 °A antisense chimeras (Barnard et al., 
1999; Torrence, 1999). One phosphorothioate ODN targeted to repetitive 
intergenic sites with the RSVgenome appeared significantly more effective 
against the virus (Jairath et al., 1997), however, development did not proceed 
into the clinic, due, in part, to side effects observed (Siddiqui-Jain et al., 2002). 
Much study is underway with the siRNAs; a recent report has showed that 
intranasal instillation of an in vitro-active siRNA into RSV-infected mice was 
significantly inhibitory to the infection (Bitko et al., 2005). Treatment begun 
four hours before the virus infection reduced the lung virus titers by 3 log10 
and prevented pulmonary pathology from developing. When therapy began 
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after virus exposure, the antiviral effect was progressively less, but 
continued to lower the virus titers.  
 
ALN-RSV01 is an siRNA  directed against the mRNA encoding the N-
protein of respiratory syncytial virus  (RSV) that exhibits specific in vitro 
and in vivo anti-RSV activity. The results of two safety and tolerability 
studies with ALN-RSV01 involving 101 healthy adults (65 active, 36 placebo, 
single- and multiple dose, observer-blind, randomized dose-escalation) have 
been described. Intranasal administration of ALN-RSV01 was well tolerated 
over a dose range up through 150 mg as a single dose and for five daily 
doses. Adverse events were similar in frequency and severity to placebo 
(normal saline) and were transient, mild to moderate, with no dose-
dependent trend. The frequency or severity of adverse events did not 
increase with increasing ALN-RSV01 exposure. All subjects completed all 
treatments and assessments with no early withdrawals or serious adverse 
events. Systemic bioavailability of ALN-RSV01 was minimal. ALN-RSV01 
appeared safe and well tolerated when delivered intranasally (DeVincenzo et 
al., 2008). It has completed Phase I of clinical trials and Phase II trials are 
currently ongoing (Empey, 2010). 
 
2.1.8.3 N-protein inhibitors 
RSV-604 is a 1,4-benzodiazepine derivative (Kelsey et al., 2004),  found to be 
unique in that it is thought to target the N-protein of RSV (Wilson et al., 
2004). The in vitro inhibitory activity is in the submicromolar range for both 
A and B strains of RSV (Wilson et al., 2004). The compound was found to be 
safe and well tolerated without any serious adverse effects in Phase I clinical 
trials in the United Kingdom (Empey et al., 2010). Pharmacokinetic studies 
from this trial suggested that once daily dosing was feasible. The compound 
   
 
22 
 
has now entered Phase II clinical trials to evaluate the antiviral effect of nasal 
and oral administration versus placebo in post-stem cell transplant patients 
and to assess the safety of the product (Empey et al., 2010). 
 
2.1.8.4 RNA-dependent RNA polymerase inhibitors 
A number of inhibitors were synthesized which targeted the guanylylation 
of viral transcripts (5’ cap) of the RSV ribonucleoprotein complex (Liuzzi et 
al., 2005). These imidazo[4,5-h]isoquinoline-7,9-dione  inhibitors may bind to 
a region in the L protein with similarities to nucleoside-diphosphate kinases 
(NDK) motifs, proteins which play a role in maintaining the balance of 
intracellular nucleotide pools. These compounds demonstrated inhibition of 
RSV replication in an ELISA-based assay, with EC50 values ranging from 
0.021 to 2.1 μmol/l. Selectivity indices ranged from 30 to 400. In a mouse 
model, lung virus titers were reduced when the compounds were 
administered intranasally 3 and 6 hours after virus exposure, then three 
times daily for 3 days at 0.4 - 4.1 mg/kg/day. A  novel benzazepine inhibitor 
of the L-protein was recently discovered from a large chemical library and 
designated as YM-53403 (Sudo et al., 2005). This compound inhibited RSV 
replication at 0.2 μmol/l in a plaque-reduction assay, however, mutant 
viruses with single point mutations in the L protein were resistant to the 
antiviral effects of the compound (Sudo et al., 2005). Timing studies 
suggested that inhibition was maximal at around 8 hours after virus 
exposure. YM-53403 is currently under ongoing preclinical trials (Empey et 
al., 2010).  
 
2.1.8.5 Inosine monophosphate dehydrogenase inhibitors 
Ribavirin is the only antiviral drug currently approved for treatment of RSV 
infections. It has inhibitory effects on a very broad spectrum of viruses, 
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including RSV (Sidwell et al., 1972). The mechanism of viral inhibition by the 
drug includes inhibition of Inosine-5′-monophosphate dehydrogenase 
(IMPDH), an enzyme which catalyzes the conversion of inosine 
monophosphate to xanthosine monophosphate. This reaction is an essential 
step in the de novo biosynthesis of guanine nucleotides leading to DNA and 
RNA synthesis. Inhibition of IMPDH thus reduces the amount of 
intracellular guanine nucleotides needed for the synthesis of RNA and DNA. 
This may consequently result in significant antiviral effects, although such 
effects may also be associated with inhibition of cell replication. It may also 
be involved in inhibition of the 5’ cap formation of mRNA, and inhibition of 
viral polymerase by the phosphorylated forms of the compound, although 
the specific mechanism by is not well documented (Sidwell, 1996). In early 
clinical studies, significant positive effects in RSV-infected infants were 
reported using ribavirin administered in a small-particle aerosol (Taber et al., 
1983; Hall et al., 1983a; Hall et al., 1983b; McIntosh et al., 1984; Barry et al., 
1986).  It is thought, however, that the outcome of the studies may have been 
affected by the use of water as the placebo, as this has a bronchoconstricting 
effect by itself. Subsequent trials using saline as the placebo did not 
demonstrate the positive effects initially observed (Broughton & Greenough, 
2004).  
Later studies have suggested that the aerosolized ribavirin may lessen post-
bronchiolitic wheezing, reactive airway disease and reduce the viral load in 
the patient (Edell et al., 1999; Guerguerian et al., 1999; Rodriguez et al., 1999; 
Edell et al., 2002). However, it has not been shown to reduce duration of 
hospitalization. There is still limited evidence of its benefits, and along with 
potential side effects and the high cost of treatment (Glanville et al., 2005), it 
is no surprise that its use has been limited to only severe cases. 
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A number of compounds in addition to ribavirin have exhibited significant 
anti-RSV activity, but these also carried their own range of harmful side 
effects. The compounds include VX-497, mycophenolic acid, mycophenolate 
mofetil, EICAR, pyrazomycin, viramidine, and LY253963 (Sidwell & 
Barnard, 2006). 
 
2.1.8.6 Polyclonal and monoclonal antibodies.  
RSV-IGIV, which consists of a high concentration of polyclonal, anti-RSV 
IgG antibodies purified from the plasma of healthy individuals (Siber et al., 
1994), became the first FDA approved agent for RSV disease prevention in 
1996. The subsequent approval of palivizumab, a monoclonal antibody 
directed at the F glycoprotein, led many to question the superiority of one 
product over the other (Morris et al., 2009). Despite similar reductions in 
hospitalizations (Morris et al., 2009), RSV-IGIV had major disadvantages 
including significant adverse events in children with congenital heart 
disease, the need for intravenous access, and the risk of infectious disease 
transmission associated with human plasma–derived products. In 1998, the 
availability of palivizumab, a safe and effective alternative, led to the 
removal of RSV-IGIV from the US market that same year (Morris et al., 2009).  
A new candidate IVIG product, RI-001 is also now being evaluated in phase 
2 clinical trials in immunosuppressed, RSV-infected patients at risk for lower 
respiratory tract illness (Clinicaltrials.gov, 2010). Although human plasma 
products harbor certain risks, stringent purification requirements have been 
implemented for all human plasma–derived products to minimize the risk of 
infection transmission (Buchacher & Iberer, 2006). Polyclonal antibodies also 
contain a mixed population of antibodies targeting multiple viral epitopes, 
thus overcoming the mutagenic potential intrinsic among viruses. These 
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studies are ongoing, and the results have not yet been published (Empey et 
al., 2010).  
 
Monoclonal antibodies, on the other hand, target a single viral epitope. 
Palivizumab, the only FDA-approved monoclonal antibody for RSV, targets 
the highly conserved F glycoprotein, inhibiting viral entry into host cells 
(Weisman, 2009). It has demonstrated no clinical benefit for the treatment of 
RSV disease and is thus indicated only for RSV prevention. Motavizumab, a 
second-generation humanized IgG1 monoclonal antibody, was developed 
from palivizumab (Abarca et al., 2009), with ∼70-fold higher affinity for the 
RSV F glycoprotein and 20-fold greater neutralizing capacity (Wu et al., 
2007). In a rat model, motavizumab had 50–100 times greater anti-RSV 
activity tract compared with palivizumab in the lower respiratory tract (Wu 
et al., 2005) and reduced RSV viral load in the upper airways, where 
palivizumab has minimal effect (Wu et al., 2007). In a large phase 3 
noninferiority study comparing motavizumab to palivizumab for RSV 
prevention in high-risk children, motavizumab demonstrated 26% fewer 
RSV hospitalizations and a 50% reduction in the incidence of RSV-specific 
outpatient lower respiratory tract infections (Carbonell-Estrany et al., 2007). 
Motavizumab also significantly reduced viral load by day 1 after treatment 
in children hospitalized with RSV, suggesting it may be beneficial for RSV 
treatment and prevention (Lagos et al., 2009). Motavizumab is currently 
pending FDA approval (Empey et al., 2010). 
 
While most RSV monoclonal antibody candidates target the more conserved 
F glycoprotein, recent evidence suggests that those targeting the G 
glycoprotein may impart dual anti-RSV activity (Empey et al., 2010). The RSV 
G glycoprotein has been shown to induce lung inflammation by binding to 
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the chemokine receptor CXC3R1 and initiating a cascade of inflammatory 
mediators (Tripp et al., 2001; Haynes et al., 2003). Although still in early 
preclinical studies, a monoclonal antibody targeting the CXC3 motif on the 
RSV G glycoprotein (mAb 131–2G) was shown to reduce both lung 
inflammation and RSV titers in BALB/c mice (Haynes et al., 2009). 
 
2.2 Honey 
2.2.1 History and traditional uses of honey 
Honey is a natural sweetener that has been used as a food and as a 
traditional medicine for at least six thousand years (Gunther, 1934; Ball, 
2007). The earliest written records of honey used as medicine is in Egyptian 
papyri and Sumerian clay tablets dated from 1900 to 1250 BC (Stomfay-Stitz 
& Kominos, 1960). Aristotle (384-322 BC) referred to honey as being a good 
salve for sore eyes and wounds (Aristotle, 350 BC),  while Dioscorides (50 
AD) described honey as being good for all rotten and hollow ulcers, 
sunburn, “spots on the face”, coughs and inflammation of the throat and 
tonsils (Gunther, 1934). Ancient Greeks are also reported to have used honey 
to treat fatigue, and athletes have been known to consume a mixture of 
honey and water before major athletic events (Wilson & Crane, 1975) The use 
of honey by the ancient Egyptians, Assyrians, Chinese, Greeks and Romans 
to treat wounds and infections of the gut has been described (Zumla & Lulat, 
1989), emphasizing the role honey must have had in medicine before the 
advent of antibiotics.  
 
Honey also has a role in present day folk medicine, where it is traditionally 
used to treat coughs and colds (Beck & Smedley, 1944) diseases of the eye 
(Fotidar & Fotidar, 1945), infected leg ulcers (Ankra-Badu, 1992), earache 
(Obi et al., 1994) and in the eyes in measles to prevent corneal scarring  
   
 
27 
 
(Imperato & Traore, 1969). A study on the specific uses of honey in 
traditional medicine in the central part of Burkina Faso by Meda et al. (2004) 
also revealed that the most common applications that were known among 
individuals in different zones included the treatment of period pains, 
postnatal disorders, gastroenteric disorders and respiratory infections.  
 
2.2.2 Antimicrobial activity of honey 
Several species have been found to be sensitive to the antimicrobial activity 
of honey and include Bacillus sp., Escherichia coli, Klebsiella sp., Micrococcus 
sp., Proteus sp., Pseudomonas sp., Salmonella sp., Sarcina sp., Seratia marcescens, 
Shigella spp., Staphylococcus sp., Streptococcus sp. and Vibria cholerae (Molan, 
1992). Several studies have also demonstrated the absence of a resistance 
mechanism to the antibacterial factors in honey. Farouk et al. (1988) showed 
that the antibacterial activities of 15 Sudanese honeys did not show selective 
inhibition when tested against S. aureus, E. coli, Bacillus subtilis, Pseudomonas 
aeruginosa and Klebsiella aerogenes. This was in contrast to four different 
antibiotics (ampicillin, cephradine, chloramphenicol and oxytetracycline) 
tested against the same organisms.  Concentrations of 1 to 4% honey have 
also been shown to inhibit a collection of methicillin-resistant S. aureus 
(MRSA) strains (Molan & Brett, 1998), which also exhibit variations in 
sensitivity to antibiotics. 
 
The reasons for the antibacterial activity of honey are diverse, and include 
factors such as an osmotic effect, acidity, the production of hydrogen 
peroxide, as well as the presence of additional non-peroxide factors. 
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2.2.2.1 Osmotic effect 
According to folklore, honey is the only food that will not spoil (Ball, 2007). 
Its low moisture content and high osmotic pressure due to the high 
concentration of sugars are defining characteristics which prevent the 
growth and survival bacteria (Ball, 2007).  Most of the carbohydrates in 
honey are monosaccharides, mainly fructose and glucose, usually in a ratio 
of 1.2:1.0, and together accounting for 85-95% of the total carbohydrate 
content (White, 1975a). Sucrose, higher sugars and disaccharides such as 
maltose, isomaltose, nigerose, turanose and maltulose are also often present 
(White, 1975b).   
 
The antibacterial property of honey, first observed by van Ketel in 1892 
(Dustmann, 1979), was assumed to be entirely due to the osmotic effect of 
honey. The low water activity of honey deprives bacteria of water needed for 
cell function, thus resulting in bacterial inhibition (Molan, 1992) Experiments 
using artificial honey, made using the same proportions of sugars found in 
natural honey, also demonstrated the same inhibiting properties, however, it 
appeared to be less potent in a couple of studies looking at its activity against 
P. aeruginosa. The minimum inhibitory concentration of artificial honey was 
found to be 20% (v/v) compared with 8% (v/v) for a lime honey (Postmes et 
al., 1993)  in one study and 22% (v/v) artificial honey compared with 5.6% 
(v/v) honey in another study (Cooper & Molan, 1999). 
 
2.2.2.2 Hydrogen peroxide 
Although honey’s high sugar content was initially thought to be the reason 
for its antibacterial activity, honey was found to have increased antibacterial 
action upon dilution, even beyond the point where osmolarity would have 
been inhibitory (Cooper et al., 1999). This increased activity was found to be 
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due to an enzyme within honey, glucose oxidase, which produces hydrogen 
peroxide when diluted, as shown in Figure 2.2. It is almost inactive in full 
strength honey (White et al., 1963).  
 
Figure 2.2 Reaction producing hydrogen peroxide. 
This reaction occurs when bees secrete glucose oxidase from their hypopharyngeal 
glands into the nectar during honey formation (source: White, 1975a; White, 1975b) 
 
 
 
 
 
 
 
 
Hydrogen peroxide acts as a powerful antiseptic and has been used for its 
antibacterial properties in clinical practice, but is only produced when honey 
is diluted as glucose oxidase is almost inactive in full strength honey 
(Harcourt, 2005). It is also harmful to tissues and can cause inflammation and 
damage, however, these effects are reduced in honey due to the inactivation 
of free iron which catalyses formation of free radicals by hydrogen peroxide  
(Buntting, 2001). The evident antimicrobial activity in diluted honey has 
implications for its use in healthcare due to the dilution effects of bodily 
fluids such as pus, lymph, plasma or stomach acids (Harcourt, 2005).  
 
2.2.2.3 Acidity and non-peroxide antibacterial components 
In addition to high osmotic pressure, and hydrogen peroxide, antibacterial 
activity was also thought to be due to the acidic pH of honey, which, as well 
as providing inhospitable conditions for bacteria, may also be aiding the 
increased lymphocyte and phagocytic activity of honey  (Ryan & Manjno, 
 
 
Glucose + Oxygen  →  Hydrogen peroxide + Gluconolactone 
                                    Glucose oxidase                                          ↓ 
              Gluconic acid 
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1977). Honey has a characteristically low pH of around 3.2 to 4.5 due to the 
presence of gluconolactone/gluconic acid which are produced enzymatically 
during the ripening of the nectar into honey (White, 1975b). The pH of most 
honeys is lower than the maximum a number of key pathogenic species can 
tolerate, however, one study looking at the relationship between pH and the 
antibacterial activity of honey failed to find a correlation (Thimann, 1963; 
Molan, 1992). 
 
Other components such as flavonoids, phenolic acids, caffeic acid, and 
ferulic acid have also been identified and isolated from honey. These 
substances have proven antibacterial activity, however, they are present in 
such low concentrations that they are not thought to have any significant 
effects (Weston, 2000). 
 
2.2.3 Methylglyoxal 
The removal of hydrogen peroxide by catalase reveals an additional 
antibacterial agent present in some honeys (Allen et al., 1991) referred to as 
the unique manuka factor or UMF. This unique activity has been found to be 
due to the presence of methyglyoxal, which is derived by the non-enzymatic 
conversion of dihydroxyacetone (Adams et al., 2008). The level of activity 
varies between different honeys, as shown in a study by Molan and Russell 
(1988) which found that  a range of honey samples  had varying levels of this 
activity from nil to almost whole of the activity in some manuka honeys. 
This variation was found to be due to the dilution of manuka honey with 
nectar derived from other floral sources, and also the different varieties of 
manuka (Leptospermum scoparium) harvested (Stephens, 2006).  
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2.2.4 More recent uses of honey 
Honey is used clinically to treat a wide variety of ailments today. Its use in 
wound care, in particular, has recently been rediscovered after being 
displaced by antibiotics in the 1940s. Its effectiveness in comparison to 
conventional wound care practices has been studied extensively, and honey 
was shown to be more effective in several studies including 17 randomised 
controlled trials involving a total of 1965 participants, and five other clinical 
trials and 16 trials on a total of 533 wounds on experimental animals (Molan, 
2006b).  Honey has also shown to promote the healing of superficial to severe 
burns more effectively compared to the control treatment using silver 
sulfadiazine (Molan, 2006a).  
 
An advantage to using honey in wound care is that allergic reactions to it are 
very rare (Kiistala et al., 1995) and it has very few adverse effects. Numerous 
reports of honey being used clinically on open wounds exist where no 
adverse reactions have been reported other than a transient stinging 
sensation described by some patients which could be due to the acidity of 
honey as stinging has not been noted after the acidity has been neutralized 
(Betts & Molan 2001).  
 
Honey has also been used therapeutically for a variety of ulcers including 
gastric ulcers, diabetic foot ulcers, leg ulcers and decubitus ulcers (Somal et 
al., 1994; Oluwatosin et al., 2000; Van der Weyden, 2003; Eddy & Gideonsen, 
2005). In the cancer setting, honey has been found to be effective for 
radiation-induced oral mucositis, periodontal gum disease, stomatitis, 
radiotherapy-induced skin reactions, malignant ulcers and infected lesions in 
paediatric oncology patients (Chiba et al., 1985; Smirnova et al., 2000; Biswal 
et al., 2003; English et al., 2004; Moolenaar et al., 2006; Simon et al., 2006). 
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Honey has also been found to be effective in expediting healing and 
reducing pain in tonsillectomy patients (Ozlugedik et al., 2006). 
 
2.2.5 Previous studies on the antiviral activity of honey 
The possibility of honey having antiviral as well as antibacterial activity has 
been looked at in a number of studies. One study which investigated the 
effect of honey on Rubella virus survival in vitro compared with thyme 
showed that honey had anti-rubella activity while thyme did not (Zeina et al., 
1996). A similar study investigated, in vivo, the effect of topically applied 
honey on recurrent attacks of labial and genital herpes lesions compared 
with acyclovir (Al-Waili, 2004). Sixteen adult patients with a history of 
recurrent attacks of herpetic lesions, 8 labial and 8 genital, were treated by 
topical application of honey for one attack and acyclovir cream for another 
attack. Results showed that for labial herpes, the mean duration of attacks 
and pain, occurrence of crusting, and mean healing time with honey 
treatment were 35%, 39%, 28% and 43% better, respectively, than with 
treatment with acyclovir. For genital herpes, the mean duration of attacks 
and pain, occurrence of crusting, and mean healing time with honey 
treatment were also 53%, 50%, 49% and 59% better, respectively, than with 
acyclovir. Two cases of labial herpes and one case of genital herpes remitted 
completely with the use of honey. The lesions crusted in 3 patients with 
labial herpes and in 4 patients with genital herpes. None of the attacks 
remitted with acyclovir cream, and all the lesions, labial and genital, 
developed crust. No side effects were observed with repeated applications of 
honey, whereas 3 patients developed local itching with acyclovir. It was 
therefore concluded that application of honey was safe and effective in the 
management of symptoms associated with recurrent herpes lesions, 
however, it was unclear whether the honey had a direct antiviral effect or 
merely reduced symptoms by means of reducing inflammation, or both. 
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To confirm the presence of antiviral activity, an in vitro study was conducted 
in order to observe the effects of honey on several strains of herpes simplex 
virus and adenovirus (Littlejohn, 2009). The study showed that the antiviral 
effect of honey could not be attributed alone to the methylglyoxal content. It 
was also shown that honey exerted its antiviral effects by more than one 
mode of action. Protection experiments showed less CPE after pre-treatment 
of the cells with honey before inoculation with virus while the neutralization 
experiments showed that treatment of the viral isolate with honey before 
using it to inoculate the cells resulted in a slower development of CPE 
compared to untreated virus. The experiments looking at prevention of 
spread of infection showed that honey had an effect against the spread of 
virus from infected cells to uninfected cells, as shown by the lower levels of 
viral CPE observed with the honey treatments compared with the untreated 
virus over the course of observation. 
 
The direct effect of the honey on the virus may be being caused by the honey 
targeting internal or external proteins of the viral particle, which causes 
unsuccessful attachment to, penetration of, or replication within the cell. It 
was also suggested that perhaps honey affects the cells by causing an 
antiviral response in the cells which then works on the viruses after 
infection. It was also thought that honey could be coating the cellular 
receptors preventing the virus from attaching to the cell. The shedding of the 
cell membrane would therefore explain the eventual development of CPE 
observed even after treatment with honey. The toxic nature of honey, 
thought to slow cellular growth, was also considered to be a factor as viruses 
replicate most efficiently in actively dividing cells.  
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2.2.6 Administration of honey into the lungs 
A study by Al-Waili (2003b) was conducted to investigate the effects of 
intrapulmonary administration of honey in sheep. Fasting blood sugar was 
estimated in six sheep after 16 hours of fasting and repeated after 30, 60, 90, 
120, 150 and 180 min without any intervention. After 1 week, sheep were 
subjected to 15 min of inhalation of distilled water using a medical ultrasonic 
nebulizer (nebulizer rate: 0-3 ml/min; particle size: mass median 
aerodynamic diameter = 4.7 μm; air volume: maximum of 17 l/min). A mask 
was fixed around the upper and lower jaw including the external nasal 
opening. Sheep inhaled through the external nasal opening while the mouth 
was closed. Fasting blood sugar was estimated before inhalation, and blood 
sugar was estimated at 30 min intervals for 3 hours. After 1 week, the same 
procedure was repeated except that instead of distilled water, sheep inhaled 
honey in distilled water (1.2 ml of honey dissolved in 1 ml of distilled water) 
for 15 minutes. Another comparable two groups of sheep, six sheep each, 
inhaled a lower concentration of diluted honey in distilled water; 0.75 ml of 
honey dissolved in 1 ml of distilled water was delivered by nebulizer to one 
group and 0.5 ml of honey dissolved in 1 ml of distilled water delivered by 
nebulizer to sheep in the second group for 15 minutes. Blood sugar 
estimation was performed before inhalation and after 30, 60, 90, 120, 150 and 
180 minutes. Close monitoring of respiratory rate, level of consciousness, 
development of dyspnea, coughing, tachypnea, rhonchi, crepitation, and 
bluish discolouration of lips and tongue was performed during and after 
inhalation. All the animals completed the experiment, and none of the sheep 
developed adverse effects during and after inhalation of water or various 
concentrations of honey. Blood sugar estimation was insignificantly changed 
in control sheep. Water inhalation did not cause any significant changes in 
blood sugars compared with fasting blood sugar and control values. Honey 
inhalation, on the other hand, caused significant lowering of blood sugar as 
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compared with control values, and values obtained after water inhalation. 
Greater effects were obtained when higher concentrations of honey were 
delivered by nebulizer.  
 
The safety and effect of intrapulmonary administration of 60% honey 
solution, 10% dextrose or distilled water on blood sugar, plasma insulin and 
C-peptide, blood pressure, heart rate, and peaked expiratory flow rate 
(PEFR) in normal and diabetic human subjects were also studied by Al-Waili 
(2003a). Results showed that in normal subjects, distilled water caused mild 
elevation of blood glucose level, mild lowering of plasma insulin, and 
significant reduction of plasma C-peptide. Dextrose inhalation caused mild 
reduction of plasma insulin and C-peptide and unremarkable changes in 
blood glucose level. No significant changes were obtained in blood pressure, 
heart rate or PEFR after distilled water or 10% dextrose inhalation but 
inhalation of honey caused lowering of blood glucose level and elevation of 
plasma insulin and C-peptide, mild reduction of blood pressure and up to 11 
and 16 percent increase in PEFR. Honey inhalation also significantly reduced 
random blood glucose level, and fasting blood glucose level three hours 
post-inhalation. Intensity of hyperglycemia was significantly lowered in 
glucose tolerance test when patients received honey inhalation. Systolic and 
diastolic blood pressure was reduced by honey inhalation in hypertensive 
patients; significant changes were obtained at 60 and 120 min after 
inhalation. No adverse effects were observed with inhalation of distilled 
water, 10% dextrose and 60% honey solution except for nasal watery 
discharge experienced by all subjects and mild cough that was experienced 
by seven subjects after honey inhalation. Overall, the results demonstrated 
that honey inhalation in humans was safe, and that it was effective in 
reducing blood glucose level in normal and diabetic subjects. It also 
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improved the glucose tolerance test, elevated plasma insulin, C-peptide and 
PEFR, and reduced elevated blood pressure in hypertensive patients. 
  
The results of this study suggest that the intrapulmonary administration of 
honey in humans is a feasible concept. If indeed proven to have antiviral 
activity against RSV, this method would be a way through which honey may 
be applied into the lungs of a patient, however, extensive clinical trials 
would need to be performed to assess any adverse effects the long-term 
inhalation of honey could have on humans.  
 
2.3 Outline of the study in this thesis 
The aim of this study is to determine whether honey does in fact have 
antiviral activity against RSV. This will be performed using cell culture 
assays and qualitative scoring of cytopathic effect (CPE). It also aims to 
determine its mode of action, whether it acts directly on the virus, the cells or 
both, in experiments that will look at the protective and neutralising 
capabilities of honey. Any results showing an antiviral effect will then be 
confirmed by enzyme-linked immunosorbent assay (ELISA), a quantitative 
approach used to detect the amount of viral antigen present in treated and 
untreated samples. 
 
Various honey types will then be tested for their ability to inhibit the 
development of CPE. This aims to determine whether their antiviral activity 
correlates with their antibacterial activity and phytochemical profiles. This 
study aims to then characterise the observed antiviral activity by looking at 
the effect of honey on the replication kinetics of RSV using real-time 
quantitative PCR. This would give a better indication of how exactly the 
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honey affects the virus as it will provide some information on changes in the 
transcription of viral genes and thus, protein synthesis.  
 
Lastly, the study also aims to determine the specific component in honey 
responsible for the observed antiviral effect by testing the activity of several 
components found within honey. This will also lead to a better 
understanding of the mechanism behind the antiviral activity. 
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Chapter Three  
                            Initial Experiments 
 
3.1 Introduction 
Initial experiments were performed in order to validate methods to be used 
in further experiments. They involved evaluating growth of the cell line and 
of the viral isolate, testing the presence of the appropriate viral isolate, as 
well as measuring the density, antibacterial activity and antioxidant capacity 
of the different types of honey used during this study. 
 
 To detect the presence of viral infection, the A549 cell line was used as it had 
previously exhibited the development of characteristic CPE caused by RSV 
(Kumar et al., 1987; Spann et al., 2004).  By examining viral CPE, observations 
were inexpensive as they could be made visually using phase contrast 
microscopy.  The CPE was qualitatively measured by visually comparing the 
level of infection against a specifically developed CPE scoring system. This 
scoring system was derived from visual observations of infected cell culture 
from the point of infection up to 5 days after infection as this was considered 
to be a feasible time period during which cultures could be observed daily. 
The observed CPE development was then confirmed and visualised prior to 
performing further experiments. This was accomplished by using a direct 
immunofluorescent antibody technique.  
 
Once the presence of the virus was confirmed, the number of viral particles 
in a suspension was determined by performing a 50% Tissue Culture 
Infectious Dose (TCID50) assay, an endpoint dilution assay that is commonly 
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used in clinical research applications. This assay tests for the highest dilution 
of the suspension which produces a CPE in 50% of the cell cultures 
inoculated. 
 
Determining the density of each honey used in this thesis was required so 
that concentrations could be standardised between honey types. The 
antibacterial activity of the different types of honey was also determined in 
order to make comparisons with any antiviral activity observed. 
 
3.2 Materials and Methods 
3.2.1 Honey 
A number of New Zealand honeys with varying phytochemical profiles were 
included to test for any high correlation between phytochemical composition 
and antiviral effect: Manuka honey with high non-peroxide antibacterial 
activity (NPA), known to contain methylgyloxal (MGO) and phenolics was 
obtained from Summer Glow Apiaries, Te Kowhai, and Watson and Son, 
Ltd., Masterton; Rewarewa honey with a high level of antibacterial activity 
due to hydrogen peroxide, high iron-binding antioxidant activity and 
phenolics from Lorimers Apiaries; Honeydew honey which shows a high 
level of antibacterial activity due to hydrogen peroxide and antioxidants 
from Tom Penrose Rangiora; and clover honey which shows no antibacterial 
activity sourced from Waitemata Honey Redvale. 
 
These honeys show a range of antibacterial levels (see Section 3.3.5) and were 
selected to allow comparisons to be made between phytochemical profiles 
and antiviral activity.   
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3.2.2 Viral isolate 
The wild-type RSV isolate used in this study was acquired from a Waikato 
Hospital patient, these were samples that had been cultured in the Virology 
Laboratory certified for use in research.  They were obtained as swab 
samples maintained in a cell culture medium.  
 
3.2.3 Cell culture materials 
The A549 cell line (human lung carcinoma epithelial cells) was kindly 
provided by the Dr. Ray Cursons (Waikato University).  This cell line was 
cultured in RPMI 1640 containing HEPES (N-2-(4-(2-hydroxyethyl) 
piperazine-N’-2-ethanesulfonic acid), obtained from Invitrogen.  This culture 
medium was supplemented with foetal calf serum (FCS) from ICP 
Biologicals at 10% or 1% to make growth or maintenance medium 
respectively, with the following antimicrobials added: 
Penicillin/Streptomycin from Gibco at a final concentration 50 μg/ml, and 
Fungizone (Gibco) at a final concentration of 2.5 μg/ml. Complete medium 
was filter sterilised using a 0.22 μm syringe filter into a sterile Schott bottle 
before being added to cells. All cell culture work was performed in a 
biosafety cabinet.  
 
3.2.4 Growth, maintenance and freezing down of cell line 
A549 cells were grown in a tissue culture flask in growth medium containing 
10% FCS (37°C, 5% CO2) for a minimum of 24 hours. Once a confluent layer 
of cells had been obtained, the culture was split by detaching the adherent 
cells from the flask by adding pre-warmed 1 mmol/l 0.05% trypsin-EDTA 
(Invitrogen) (2 ml for 25 ml flask) into the flask and incubating it at 37°C for 
2-3 minutes, while gently rocking the flask at intervals. Once cells were 
detached from the bottom of the flask, half of the cell suspension was 
aspirated from the flask, and 4 ml of growth medium was added to the 
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remaining suspension. The flask was then put back in the incubator and the 
cells left to grow. 
 
To prepare a plate for experiments, once the cells had detached from the 
bottom of the flask, the cell suspension containing detached cells was diluted 
with an appropriate amount of growth medium and distributed into the 
wells of the plate at an average density of 4.1 x 105 cells per ml.  
 
To prepare a storage culture, after detaching the cells, 6 ml of growth 
medium was added to the cell suspension and the suspension was loaded 
into 1.5 ml Eppendorf centrifuge tubes and centrifuged for 2 minutes at 6 000 
rpm.  The cells were re-distributed using a Pasteur pipette in 1 ml freezing 
medium (10% dimethyl sulphoxide (DMSO) in FCS), and transferred to 1.5 
ml freezing cryovials. The cells were brought down to a low temperature by 
first placing in a cell freezing chamber, and then stored indefinitely at -80°C.  
 
To revive the stored cells, cryovials were thawed in a 37°C waterbath for 5 
minutes before the contents were transferred into a 25 ml cell culture flask 
containing 4 ml pre-warmed growth medium. 
 
3.2.5 Growth, maintenance and freezing down of viral isolates 
To establish viral stocks, cells were detached from the tissue culture flask 
and supplemented with growth medium as described in Section 3.2.4. The 
cell suspension was distributed in appropriate volumes to a number of cell 
culture flasks and was incubated overnight at 37°C.  Once the cells were 
confluent, the medium was replaced with maintenance medium and 200 µl 
of the appropriate viral isolate from the samples obtained from the Waikato 
Hospital Virology Laboratory was added. The cells were further incubated at 
37°C and observed daily for characteristic morphological changes caused by 
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the virus (CPE).  Once a moderate level of CPE was reached (see Section 
3.3.1), the culture medium was distributed into a number of Eppendorf 
centrifuge tubes and frozen at -80°C until required.  
 
3.2.6 Direct fluorescent antibody (DFA) test 
Cells were grown on round 13 mm coverslips in 24-well cell culture plates as 
in Section 3.2.4. Once confluent, the cells were infected with 200 μl of viral 
stock suspension for 1 hour at 37°C. The cells were washed once with sterile 
PBS (8 g/l sodium chloride, 1.21 g/l dipotassium phosphate, 0.34 g/l 
potassium dihydrogen phosphate made up to 1 litre with water and filter-
sterilised, pH 7.3) and the supernatant was then replaced with maintenance 
medium. The plates were then incubated at 37°C in a 5% CO2 incubator and 
observed daily for CPE development. Cells that were not infected with RSV 
served as controls. For this study, a Millipore Light Diagnostics RSV DFA Kit 
(Catalog no. 3125, Lot no. JH1643661) was used.  
 
When the CPE in the infected cells had reached a score of 3, the medium was 
aspirated off and the cells washed once with wash buffer prepared using 
materials provided in the kit (100 X Tween 20/Sodium Azide Solution 
(Catalog No. 5037) diluted 1:100 in PBS buffer (Catalog No. 5087)). After 
aspirating the wash buffer, the cells were then fixed by adding 80% acetone 
to each well. The acetone was left on for 10 minutes before it was aspirated 
off and the plate thoroughly air-dried. Once dry, the cover slips were 
removed from the wells and put on a petri dish. A drop of antibody solution 
was applied on top of each cover slip. The petri dish was then put in a 37°C 
incubator for 20 minutes. After 20 minutes, the cover slips were rinsed with 
wash buffer three times and rinsed gently with water and dried before being 
mounted onto a glass slide with mounting fluid (Catalog No. 5013), also 
included in kit. The slides were then viewed under a fluorescent microscope. 
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3.2.7 Determining viral titre 
A tube of viral stock suspension prepared as described in Section 3.2.5 was 
thawed at room temperature.  Once thawed, 100 µl of the stock viral solution 
was serially diluted from 10-1 to 10-6 in maintenance medium.  Confluent 
A549 cells prepared in 24-well plates were inoculated with 1 ml of 10-1 to 10-6 
dilutions in quadruple.  The plates of inoculated A549 cells were then 
incubated at 37°C (5% CO2) and observed daily for development of 
characteristic CPE. 
 
The lowest dilution of viral stock suspension that could still induce a CPE 
was taken as the maximum dilution that would lead to infection.  This was 
termed the TCID50 as it was the minimum concentration of virus required to 
detect viral CPE, and gave a rough indication of the overall concentration of 
virus present within the stock suspension. 
 
3.2.8 Measuring the density of honey 
To determine the density of each type of honey, 5 ml of distilled water was 
measured into a 25 ml measuring cylinder and 5 g of honey was added at to 
the cylinder, all at room temperature. The new volume within the measuring 
cylinder was recorded. 
 
3.2.9 Measuring the antibacterial activity of honey 
The antibacterial activity, with and without catalase added to remove 
activity due to hydrogen peroxide, was measured in an agar well diffusion 
assay as described by Allen et al. (1991).  The activity measured by this 
method is expressed as the concentration of phenol with equivalent 
antibacterial activity. 
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3.2.10 Measuring the antioxidant activity of honey 
The antioxidant activity of the different honey types was measure by a 
modification of the method of Baltrusaityte (2007) as described in Brangoulo 
& Molan (2011), in which the removal of the coloured ABTS (2,2'-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid)) radical was measured 
spectrophotometrically. The trolox equivalent antioxidant capacity (TEAC) 
values were expressed as mmol trolox per kg of honey. 
 
3.2.11 Determining the A549 cell line tolerance to honey 
Adding high concentrations of honey to the media can cause changes to the 
cells such as shrinking as a result of osmotic action. Thus, the maximum 
concentration of honey at which the cells were displaying no morphological 
changes was determined. This was to ensure that all morphological changes 
recorded were due to the activity of the virus and not the honey.  
 
A549 cells were seeded in 24-well plates as described in Section 3.2.4 and left 
in a 37°C incubator overnight. Once confluent, 0% to 4% honey solutions in 
maintenance medium were prepared using various honeys using the density 
outlined in Section 3.2.4. These were mixed and filter-sterilized before being 
used to replace the growth medium in the cell culture plates. The plates were 
then incubated at 37°C (5% CO2) for a few days and observed daily for 
changes in cellular morphology. Evidence of morphological change was 
recorded using the CPE scoring system outline in Figure 3.1. This experiment 
was performed in triplicate and repeated on a different day. 
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3.3 Results 
3.3.1 Cytopathic effect (CPE) scoring  
This investigation aimed to monitor the progression of infection in cells 
caused by RSV and classify the observed morphological changes into a 
scoring system that can be used in subsequent experiments. As outlined in 
Section 3.2.4, A549 cells were cultured in 24-well plates. Once confluent, the 
growth medium was removed and replaced with 1 ml viral suspension 
diluted to 10-1 in maintenance medium. Cells serving as controls were not 
inoculated. The plate was then further incubated at 37°C (5% CO2) and 
observed daily for CPE development. This experiment was performed in 
triplicate and repeated in triplicate twice on different occasions. 
 
The CPE scoring system is illustrated and presented in Figure 3.1. The results 
of the experiment following the progression of RSV infection are shown in 
Figure 3.2. Controls did not show any visible changes in morphology, and no 
differences were found between replicates. The bars in the graph represent 
the mean of triplicates from three different days of experimentation. All 
replicates demonstrated a lack of CPE after 24 hours, however low levels of 
CPE became evident two days after infection. Within 3 days, cell cultures 
were showing moderate CPE and by day 4, high levels of CPE were 
observed with most of the cells being detached from the bottom of the wells 
at this point. 
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Figure 3.1 CPE development in A549 cells after RSV infection. 
a) CPE 0, b) CPE 1, c) CPE 2, d) CPE 3, e) CPE 4, f) CPE 5 
 
 
 
Morphology Score 
100% of monolayer intact  0 
90% of monolayer intact, 10% dead 1 
80% of monolayer intact, 20% dead  2 
75% of monolayer intact, 25% dead 
(cells also start to appear elongated) 
3 
50% of monolayer intact, 50% dead 4 
25% of monolayer intact, 75% dead  5 
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Figure 3.2 CPE resulting from infection of A549 cells with RSV. 
Each bar represents the mean ± SEM of triplicates on each of the three days of 
experimentation. 
 
 
 
Based on the results from this experiment, it was concluded that tests 
looking at treatment effects on CPE development would have to be run for at 
least 4 days as this was how long it took the isolate to cause severe CPE on 
A549 cells.  
 
3.3.2 Confirmation of presence of virus using direct fluorescent antibodies         
As outlined in Section 3.2.6, DFA tests were performed on normal A549 cells 
and cells infected with RSV to confirm that the CPE observed is caused by 
the appropriate virus. The antibody solution included in the Millipore Light 
Diagnostics RSV DFA kit used for this study comprises four different antibodies 
to ensure that it detects all strains of RSV including all A and B types. The various 
antibodies together recognize the fusion protein, the glycoprotein and the nuclear 
protein of the RSV. The antibodies which bind the viral antigen are labelled 
with fluorescein isothiocyanate (FITC) which fluoresces apple-green when 
illuminated with ultraviolet light, while uninfected cells stain dull red due to 
the presence of Evans blue. This experiment was performed in triplicate. 
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Figure 3.3 Cells with no virus (left) and cells infected with RSV (right) 
stained using direct fluorescent antibodies 
  
 
 
The DFA tests confirmed the presence of RSV virus in cells exhibiting CPE. 
The control cells which were uninfected and exhibited no CPE looked dull 
red, showing the absence of virus in the sample. This technique was a very 
easy and fast way to confirm the presence of virus. 
 
3.3.3 Viral Titre 
As described in Section 3.2.5, viral stock suspension was thawed at room 
temperature and used to serially inoculate confluent A549 cells on a 24-well 
plate. The cells were then incubated at 37°C and observed daily for the 
development of characteristic CPE development. This experiment was 
performed in triplicate. The results of the CPE scores observed with serial 
dilutions of each virus are shown in Figure 3.4. 
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Figure 3.4 CPE resulting from serially diluted RSV at 24, 48, 72, 96 and 120 
hours after infection 
 
 
 
The results from the plates were then analysed using the Reed-Muench 
method for calculating TCID50. The data shown in Table 3.1 was used to 
demonstrate the calculation by this method.  
 
Table 3.1 Infectivity of RSV at various dilutions 
Log of 
virus 
dilution 
Infected 
test units 
Cumulative 
infected 
(A) 
Cumulative 
non-infected 
(B) 
Ratio of 
A/(A+B) 
Percent 
infected 
-1 5/5 20 0 20/20 100% 
-2 5/5 15 0 15/15 100% 
-3 5/5 10 0 10/10 100% 
-4 5/5 5 0 5/5 100% 
-5 0/5 0 5 0/5 0% 
-6 0/5 0 10 0/10 0% 
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The dilution in the table that corresponds to the 50% end point lies 
somewhere between the 10-4 (100% infected) and 10-5 (0% infected) dilutions.  
 
The proportionate distance between these two dilutions was calculated in 
the following manner (Mahy & Kangro, 1996): 
 
 
 
 
Therefore: (100% - 50%) / (100% - 0%) = 0.5 
 
Given that the log of the dilution above 50% is -4, the proportionate distance 
is 0.5 and the log of the dilution factor is -1 (serial 10-fold dilutions were 
used), the 50% end point is calculated using the following equation: 
 
(log dilution above 50%) + (proportionate distance x log dilution factor) = log ID50 
(-4) + (0.5 x -1.0) = -4.5 
 
The 50% endpoint is calculated to be 10 -4.5. The virus suspension (1 ml) will 
contain the reciprocal of the calculated dilution, which is 104.5 TCID50 units. 
 
3.3.4 Honey density 
As described in Section 3.2.8, the density of each honey type was established 
using a displacement method. The different types of honey used included 
Manuka honeys M117, M115 and M157, Rewarewa honey RE32, Honeydew 
honey HD19 and clover honey CL24. All the honeys measured gave a 
volume increase of 3.5 ml when added to water. The following formula was 
used to calculate their density: 
 
_____(% positive above 50%) – 50%_________ 
(% positive above 50%) – (% positive below) 
50%) 
= Proportionate distance 
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Density = Old weight/ (New volume - Old volume) 
    = 5/(8.5 – 5) 
    = 1.43 g/ml     
The density of all the honeys tested was therefore concluded to be 1.43 g/ml. 
 
3.3.5 Antibacterial and antioxidant activities of the honeys used 
The antibacterial and antioxidant activities found for the honeys used in this 
study are shown in Table 3.2.  
 
Table 3.2 Antibacterial and antioxidant activity of the honeys used 
TA= total antibacterial activity, NPA= non-peroxide antibacterial activity, TEAC= 
trolox equivalent antioxidant capacity. 
 
Honey TA (w/v) phenol % NPA (w/v) TEAC mmol/kg 
M157 23.2 21.9 0.62 
M115 15 15.8 1.2 
M117 27 25.9 1.6 
RE32 21.9 0 2.2 
CL24 0 0 0.48 
HD19 15.1 0 1.73 
 
The Manuka honeys have generally high total (the majority of which is non-
peroxide) and non-peroxide antibacterial activity.  The other honeys 
generally have lower levels of total antibacterial activity and do not have 
non-peroxide antibacterial activity, however, they have been found to have 
characteristically high levels of antioxidant capacity. 
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3.3.6 Cell tolerance to honey 
The results from the investigation determining the maximum concentrations 
of honey the A549 cells tolerated before showing changes in morphology are 
shown in Figure 3.5.  
 
Figure 3.5 A549 cell line tolerance to a range of honey types 
The results represent the mean ± SEM of triplicates from experiments performed on 
two different days. 
 
 
 
It was concluded that the maximum concentration the cells could tolerate 
from most honeys was 2%. Cells were able to tolerate clover honey (CL24) 
up to 3%. 
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Chapter Four  
                        The antiviral activity of honey 
 
In order to evaluate the antiviral activity of honey, a range of methods were 
used to examine different aspects of the hypothesised antiviral effect.  The 
methods aim to investigate the inhibitory, protective, and neutralising 
capacities of honey, with the goal of gaining a better understanding of the 
underlying nature of its antiviral activity. 
 
These primary experiments used cell culture and one type of honey to 
investigate the feasibility of methodology, and find methods that were most 
suitable to be used in subsequent work with a range of honey types.   
 
4.2 Inhibition of development of viral infection 
4.2.1 Introduction 
This experiment aimed to test whether incubation of RSV- infected cells with 
honey could prevent or slow down the rate of CPE development compared 
with infected cells without honey. This type of investigation may possibly 
show whether honey can be used as a treatment for viral infections once 
infection has taken place. It was decided that, to mimic real-life situation, the 
cells would first be inoculated with virus for 1 hour before honey is applied. 
However, it was discovered that the rate of CPE development was much 
slower than previously observed (Section 3.3.1) due to the shorter 
inoculation time. A number of methods were then tested to determine the 
best way to ensure the fast development of CPE so that experiments could 
run for as little time as possible.  
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4.2.2 Materials and Methods 
a) First experiment 
A549 cells were seeded into a 24-well plate and incubated at 37°C overnight 
as described in Section 3.2.4. Once confluent, the growth medium was 
removed from the cells. Viral stock suspension was diluted ten-fold in 
maintenance medium and 200 μl was added to each well.  The plate was 
then put in a 5% CO2 incubator set at 37°C for one hour. After one hour, the 
inoculum was aspirated off, the cells were washed once with sterile PBS (see 
Section 3.2.6) which was then replaced with 1 ml of maintenance medium 
containing varying concentrations of M115 honey. The plate was then 
incubated and observed daily for CPE development. This experiment was 
performed in triplicate. 
b) Second experiment 
The second experiment was carried out in the same way as the first, but after 
the suspension was added to each well, the plate was then centrifuged at 
20°C at 2 000 rpm for 15 minutes before continuing with the rest of the 
procedure.  
c) Third experiment 
The third experiment was carried out in the same way as the first, but 
undiluted viral stock suspension (200 μl) was added to each well instead of 
diluted viral stock suspension. 
d) Further observations on the inhibitory activity of honey against RSV 
Further observations on the inhibitory effect of honey against RSV were 
made using the method which was found to result in a more rapid 
development of CPE.  This experiment was performed in triplicate and 
repeated on a different day. 
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4.2.3 Results 
The results of the experiments are presented as plots of developing CPE in 
Figures 4.1 to 4.4.  The controls of each honey concentration without virus 
did not cause any visible morphological changes of the cells over the 
observation period.  The different inoculation methods all resulted in 
different rates of CPE development, with the fastest being shown in Figure 
4.3, where 200 μl of undiluted viral supernatant was used to inoculate the 
cells for one hour. Results from further observations using this method are 
shown in Figure 4.4 and demonstrate an inhibition of RSV as a result of 
treatment with honey.  
 
Figure  4.1 CPE development in A549 after exposure to viral supernatant 
diluted to 10-1 for 1 hour prior to addition of honey solution 
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Figure 4.2 CPE development in A549 cells after inoculation with viral 
supernatant diluted to 10-1 and centrifuged for 15 minutes prior to addition 
of honey solution 
 
 
 
Figure 4.3 CPE development in A549 cells after exposure for 1 hour to 
undiluted viral supernatant prior to addition of honey solution 
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Figure 4.4 Further observations on the inhibitory effect of honey on CPE 
development in RSV-infected A549 cells 
 
 
 
4.2.4 Discussion 
The first three experiments all demonstrated the inhibitory effect of honey on 
RSV, however, differences in results were observed depending on the 
method of inoculation with virus. Diluting the viral supernatant ten-fold and 
having shorter inoculation times resulted in slow CPE development, with 
cells showing only moderate infection at 7 days post-infection. This suggests 
that this strain of RSV requires a long inoculation time. Using undiluted 
virus increased the rate of CPE development, resulting in high levels of CPE 
by 5 days post-infection and was thus employed in further experiments.   
 
The honey was shown to have an effect against the progression of viral 
infection, as shown by the lower levels of viral CPE observed with the honey 
treatments compared with the untreated virus over the course of 
observation. Each honey treatment suppressed the severity of viral CPE, 
with the higher concentration having the greatest effect.  
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The delayed CPE development in honey-treated cells suggests that the honey 
could have more than one mode of action. It could be acting directly on the 
virus to neutralise it, or it could be acting on the cells, possibly causing 
changes in the expression of genes involved in the antiviral response, such as 
NF-κB – or both. To determine the mode of action of honey, further 
experiments looking at the protective and neutralising abilities of honey 
were performed. 
 
4.3 Protection of the cells from viral infection 
4.3.1 Introduction 
The ability of honey to protect the cells from infection by viruses was 
evaluated through the culturing of confluent A549 cells within honey-
containing growth medium, followed by removal of this medium before 
inoculation of the cells with the viral isolate.  This approach aimed to test 
whether pre-treatment of the cells with honey can prevent the development 
of viral CPE following inoculation of the cells with virus.  A positive result 
obtained in such an investigation can provide support towards the use of 
honey as a preventative or prophylactic treatment for individuals at risk of 
such viral infections. This experiment also sought to determine whether 
honey acts on the cells directly to cause an antiviral response, resulting in the 
slower development of CPE previously observed in Section 4.2.  
 
4.3.2 Materials and Methods 
Growth medium was prepared containing 0%, 1%, and 2% concentrations of 
Manuka honey M115 and was filter-sterilised.  Stocks of A549 cells were 
prepared for seeding into 24-well plates as described in Section 3.2.4.  
Appropriate volumes of the cell suspension were mixed with the honey 
solutions based on the size of the flask, and were then distributed in volumes 
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of 1 ml into a 24-well plate. The plate was incubated overnight at 37°C (5% 
CO2). Once the cells were confluent, the honey-containing growth medium 
was removed and replaced with 200 μl of viral suspension and incubated at 
37°C (5% CO2) for 1 hour.  After 1 hour, the inoculum was removed and the 
cells were washed once with PBS. Maintenance medium (1 ml) was added to 
each well. The plate was returned to the incubator and observed daily for 
CPE development. As controls, cells treated with each concentration of 
honey were also tested without subsequent addition of virus. The 
experiment was performed in triplicate within each plate and repeated on a 
different day.  
 
4.3.3 Results 
The results of the experiments are presented as plots of developing CPE in 
Figure 4.5.  
 
 Figure 4.5 CPE development from exposure to RSV after pre-treatment of the 
cells with various concentrations of honey 
Each bar represents the mean ± SEM of triplicates from each of the two days of 
experiments. 
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The results from the replicates were identical for each day, but differed 
between days. No treatment effect was observed. The controls of each honey 
concentration without virus did not show any visible morphological changes 
of the cells over the observation period. 
 
4.3.4 Discussion 
This experiment has demonstrated that the honey was unable to protect the 
cells from RSV infection. These results are contrary to previous findings by 
Littlejohn (2009), whose similar study on herpes simplex virus and 
adenovirus showed that incubation of A549 cells with honey prior to 
infection resulted in a slower development of CPE. This indicates that 
different viruses may be affected by honey differently. It also suggests that 
perhaps honey acts on the virus particle directly, rather than causing 
changes to the cell which indirectly inhibit its replication. This includes 
changes such as upregulation or downregulation of specific genes involved 
in the antiviral response, however, it is also possible that an infection needs 
to be present in the first place for honey to be able to illicit an antiviral 
response in the cells. Future studies would benefit from looking at changes 
in the expression of genes involved in the antiviral response to determine if 
honey has any effect on them. 
 
Based on the results obtained from this experiment, it is unlikely that honey 
would be an effective prophylactic agent for individuals at high risk of RSV 
infection, however, experiments with primary cell cultures and animal 
models would give a better indication of this.    
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4.4 Neutralisation  
4.4.1 Introduction 
This experiment aimed to test whether honey would has any neutralising 
activity against RSV. It is hypothesised, based on the results from Section 4.2 
and 4.3, that honey affects the virus directly to inactivate it, thus causing 
inhibition of CPE development. In this experiment, the viral isolate was 
exposed to various concentrations of honey for a one hour before being used 
to inoculate the cells. CPE development was then monitored on the days 
following inoculation of the cells to determine whether neutralisation, 
observed as the absence or delay of viral CPE development, has occurred. If 
neutralisation is found to occur with a short period of exposure of virus to 
honey, this experiment will show that it may be possible for the virus to be 
inactivated between being shed and infecting other cells. 
 
4.4.2 Materials and Methods 
A549 cells were prepared and grown overnight in 24-well plates at 37°C until 
confluent as described in Section 3.2.4. Sterile bijoux bottles were used to 
prepare filter-sterilised honey solutions containing 0%, 1% and 2% honey in 
maintenance medium. In an Eppendorf microcentrifuge tube, viral 
supernatant (200 μl) was added to each honey solution (800 μl). These 
solutions, as well as honey solutions without virus serving as controls, were 
incubated with shaking for 1 hour using a shaking incubator at level 1 set at 
37°C. At the conclusion of the neutralisation period, the growth medium was 
removed from the cells which were then incubated with 1 ml of each of viral-
honey solution for 1 hour at 37°C. After one hour, the inoculum was 
removed, the cells washed once with PBS and 1 ml maintenance medium 
was added. The plates were left in a 37°C, 5% CO2 incubator and 
observations were made daily to record the development of CPE until a high 
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level of CPE had developed with the untreated virus (0% honey). Each 
experiment was completed in triplicate and repeated in time.  
 
4.4.3 Results 
The results from the neutralisation experiment are shown in Figure 4.6. It 
shows a treatment effect caused by honey, where CPE development in cells 
infected with honey-treated virus was much slower compared to that treated 
with maintenance medium only.  
 
Figure 4.6 CPE development in A549 cells infected with RSV pre-treated with 
0%, 1% and 2% M115 hone 
Each bar represents mean ± SEM of triplicates from one day of experimentation 
 
 
 
Treatment with honey at 2% resulted in the greatest inhibition, while 1% 
honey caused moderate inhibition. 
 
4.4.4 Discussion 
These experiments indicate that honey had a significant inhibitory effect on 
RSV as demonstrated by the slower progression of CPE development in 
treated virus compared with untreated virus. In each experiment, 
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suppression of viral CPE was observed with the honey treatments, and 
further evidence of neutralisation was seen with increasing concentrations of 
honey. The resulting CPE levels reached during the duration of the 
experiments are similar to the levels observed in the first tests looking at the 
prevention of spread of virus. The findings from this experiment therefore 
support the hypothesis that the honey could be acting on the virus directly, 
however, the effects observed may have also been due to the presence of 
honey, which would have been in contact with the cells for one hour.  
 
The results from this experiment suggest that honey can potentially be used 
as an antiviral agent to aid the immune system in response to viral infection 
by RSV. It may slow down the progression of infection by neutralising viral 
particles that have been shed, allowing the body’s own defences to help 
eliminate the virus. 
 
4.5 Addition of honey to moderately infected cells 
4.5.1 Introduction 
This experiment aimed to determine whether would be an effective 
treatment for patients already suffering from the symptoms of an RSV 
infection. This was evaluated by observing the effects of adding honey to 
cells exhibiting a moderate level of CPE. If found to be effective, this 
experiment would highlight the potential of using honey to treat otherwise 
healthy individuals who are likely to seek medical help only once the 
symptoms of infection had become apparent.   
 
4.5.2 Materials and Methods  
A549 cells were prepared and grown overnight in 24-well plates at 37°C until 
confluent as described in Section 3.2.4. Once confluent, growth medium was 
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aspirated off and the cells, apart from the controls, were inoculated with 
200 μl of viral supernatant for 1 hour in a 37°C, 5% CO2 incubator. After one 
hour, the inoculum was removed and replaced with 1 ml of maintenance 
medium. The plate was then placed back in the incubator and the cells were 
observed daily for CPE development. Once the infected cells had reached a 
CPE score of 3, the supernatant was removed and replaced with 0%, 1% and 
2% M115 honey solutions. The plate was then placed back in the incubator 
and observed daily for CPE development. The experiment was performed in 
triplicate and repeated on a different day. 
 
4.5.3 Results 
The results showing the effects of adding honey to moderately infected cells 
is shown in Figure 4.7. The asterisk indicates the day maintenance medium 
was replaced with honey solutions containing various concentrations of 
honey, which was when most of the cells were showing signs of moderate 
RSV infection (CPE 3).  
 
Figure 4.7 Effects of adding honey to moderately infected cells 
Asterisks indicate when maintenance medium was replaced with honey solutions. 
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The normal development of CPE was found to be slower in this experiment, 
with the untreated cells reaching CPE 5 only after 7 days. The results from 
the experiment show that the addition of honey slows down any further 
development of CPE, with the addition of 2% honey halting its development 
for the duration of the experiment. No differences were found between 
replicates and repeats, and no morphological changes were observed in 
control cells not infected with virus. 
 
4.5.4 Discussion 
The slower development of CPE observed even in the control cells is likely to 
be due to the replacement of maintenance medium, thereby removing a large 
proportion of viral particles present in the culture. The results obtained from 
this experiment have demonstrated the ability of honey to inhibit further 
progression of infection in cells already exhibiting moderate CPE levels. 
Considering that most healthy individuals will only seek professional 
medical help for RSV infection once symptoms are already present, the 
results from this experiment demonstrate its potential benefits for use as a 
therapeutic. The use of honey to suppress the progression of RSV infection in 
humans may have implications on the morbidity and mortality rate of 
patients, allowing the immune system some time to eliminate the virus, 
possibly resulting in a quicker recovery. Further in vivo investigations would 
need to be performed to see whether the same effect will be observed in 
animal models. 
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Chapter Five  
The antiviral activity of different honey types 
 
5.1 Inhibition of development of viral infection by different 
types of honey 
5.1.1 Introduction 
It has been established by the current study that honey can temporarily 
suppress the development of CPE.  It was desirable to test a range of honeys 
with varying phytochemical profiles to determine whether some honeys can 
cause greater suppression or neutralisation of the virus than others. It was 
hypothesised that the observed antiviral activity can be linked to a 
characteristic property within the honey, such as high levels of hydrogen 
peroxide, phenolics, antioxidants or non-peroxide activity due to the 
presence of methylglyoxal. 
 
5.1.2 Materials and Methods 
A549 cells were seeded into 24-well plates and incubated at 37°C overnight 
as described in Section 3.2.4. Once confluent, the growth medium was 
removed from the cells. Viral supernatant (200 μl) was added to each well.  
The plate was then put in a 5% CO2 incubator set at 37°C for one hour. After 
one hour, the inoculum was aspirated off using a plastic Pasteur pipette, 
washed with sterile PBS (see Section 3.2.6) and replaced with 1 ml of 
maintenance medium containing 2% of different types of honey. The honeys 
used were Manuka honeys M117, M157 and M115, Rewarewa honey RE32, 
Honeydew honey HD19 and clover honey CL24. These honeys were chosen 
based on their distinct phytochemical profiles as outlined in Section 3.2.1. 
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The plate was then returned to the incubator and observed daily for CPE 
development. This experiment was performed in triplicate on a 24-well plate 
and repeated in triplicate on a different day. Controls without honey and 
without virus were included. 
 
5.1.3 Results 
The results are presented in Figures 5.1 as plots of CPE development.  
Manuka honey M117 was observed to have the greatest inhibitory effect on 
RSV, with treated cells exhibiting only a CPE score of 1 at Day 5 post-
infection. Treatment with Manuka honeys M115, M157, Rewarewa RE32 and 
Honeydew HD19 caused similar levels of inhibition, with treated cells 
showing moderate levels of infection by Day 5 (CPE 2 to 3). Clover honey 
CL24 was observed to have the least effect on RSV, only resulting in mild 
inhibition, and treated cells displaying moderate to severe levels of CPE at 
the conclusion of the experiment (CPE 3 to 4).  
 
Figure 5.1 CPE development in A549 cells in the presence of various types of 
honey after infection with RSV. 
Experiment was performed twice on different days (A and B). Each bar represents 
mean ± SEM of triplicates from one day of the experiment. 
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No morphological changes of the cells were observed in the controls without 
virus. 
 
5.1.4 Discussion 
In this experiment, all honeys were shown to have some inhibitory effect 
against RSV. The Manuka honey with high-NPA activity, M117, had the 
greatest effect on the resulting severity of viral infection. Manuka honeys 
M157 and M115, which had mid-range NPA, also slowed down CPE 
development, however, their effect was similar to two of the other honeys 
tested, Rewarewa RE32 and Honeydew HD19, which do not have NPA. 
Clover honey CL24 had the least effect, with the cells exhibiting moderate to 
severe CPE by Day 5.  
 
The results from this experiment suggest that there is some correlation 
between a honey’s antibacterial activity and its antiviral activity. The honeys 
shown to have the greatest effect in this experiment were honeys which had 
the highest total antibacterial activity ratings as outlined in Section 3.3.5.  
Similarly, CL24, which was shown to have the least effect on development of 
0
1
2
3
4
5
1 2 3 4 5
C
P
E 
sc
o
re
Days after infection
M117
M115
M157
RE32
HD19
CL24
No honey
B 
                                 
 
69 
 
CPE, had no observable antibacterial activity. The other honeys which were 
shown to have similar effects on reducing viral CPE have different 
antibacterial activity ratings, however, due to the limitations of the CPE 
scoring system, the differences in their activity against RSV may be more 
difficult to determine by eye. A quantitative test such as an enzyme-linked 
immunosorbent assay (ELISA) would allow for a more thorough analysis to 
determine the potency of each honey type.   
 
Looking at the different types of Manuka honey used in this experiment, it is 
possible that antiviral activity may be directly correlated with the amount of 
methylglyoxal (MGO) present in that type of honey. Investigating the effect 
of adding MGO to low activity Manuka honeys will provide a better look at 
its role in inhibiting viruses. High levels of phenolic compounds are also 
found in Manuka honey, and may also be a contributing factor in the 
observed antiviral effect (Littlejohn, 2009). It would therefore be of value to 
look at the inhibitory effects of adding phenolics, as well as other 
components – such as hydrogen peroxide, antioxidants and proteins –
abundant in the non-Manuka honeys which also exhibited an antiviral effect.  
 
5.2 Neutralisation of RSV using different types of honey 
5.2.1 Introduction 
This experiment aimed to investigate the neutralisation capabilities of 
various honey types. It is hypothesised that the ability of each honey to 
neutralise RSV will reflect its ability to suppress the development of CPE as 
observed in Section 5.1.3. 
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5.2.2 Materials and Methods 
A549 cells were grown overnight as described in Section 3.2.4. Bijoux bottles 
were used to prepare honey solutions containing 2% honey in maintenance 
medium. The honeys used were as described in Section 5.1.2. In an 
Eppendorf microcentrifuge tube, viral supernatant (200 μl) was added to 
each honey solution (800 μl). These solutions, as well as honey solutions 
without virus serving as controls, were incubated with shaking for 1 hour 
using a shaking incubator at level 1 set at 37°C. At the conclusion of the 
neutralisation period, the growth medium was removed from the cells which 
were then incubated with 1 ml of each of viral-honey solution for 1 hour at 
37°C. After one hour, the inoculum was removed and replaced with 1 ml 
maintenance medium. The plates were left in a 37°C, 5% CO2 incubator and 
observations were made daily to record the development of CPE until a high 
level of CPE had developed with the untreated virus (0% honey). Controls 
with each honey solution without virus were also included. Each experiment 
was completed in duplicate and repeated in duplicate on a different day. 
 
5.2.3 Results 
The results from the experiment looking at the neutralisation capabilities of 
different types of honey are shown in Figure 5.2. 
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Figure 5.2 CPE development in A549 cells infected with RSV which had been 
pre-treated with different types of honey at 2% 
Experiment was performed twice on different days (A and B). Each bar represents 
mean ± SEM for triplicates from one day of the experiment. 
 
 
 
 
 
The high-NPA Manuka honey M117 had the greatest effect on the virus, 
while clover honey CL24 had the least effect. The mid-range Manuka honeys 
caused similar levels of inhibition to the Rewarewa honey and Honeydew 
honey examined. 
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5.2.4 Discussion 
This experiment looked at the neutralisation capabilities of different types of 
honey. The results observed were similar to those observed in Section 5.1.3 
where the honey treatment was added after inoculation with the virus. The 
high-NPA Manuka honeys generally had a greater inhibiting effect, while 
the other honeys exhibited similar levels of antiviral activity. The clover 
honey used in this experiment had little inhibitory effect on RSV, with the 
cells showing moderate CPE by Day 5. As previously discussed in Section 
5.1.4, the methylglyoxal in Manuka honeys may be the component 
responsible for the greater inhibition observed in these honeys compared 
with non-Manuka honeys. Future experiments will need to confirm this. The 
antiviral activity observed in the other honeys tested may be due to a 
number of factors, since each one has a phytochemical profile distinct from 
the others. Other components found in these honeys, such as hydrogen 
peroxide, antioxidants and phenolics should also be examined in future 
investigations.   
 
The experiments in this chapter have demonstrated that high-NPA Manuka 
honeys would be the best candidates for use as treatment in RSV infection, 
clinical studies are required to verify this.   
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Chapter Six  
A quantitative study on the antiviral activity 
of honey 
6.1 Introduction 
Enzyme-linked immunosorbent assays (ELISA) can be used as a sensitive 
measure to detect the amount of a specific antigen within a sample.  The 
whole ELISA experimental process includes several steps, including the 
blocking of binding sites, the immobilization of an antibody on the plate, the 
binding between the immobilized antibody and its antigen and the detection of 
binding signals.  
 
Ideally, the enzymes used to label the antigen or antibody should be stable, 
safe and inexpensive. These enzymes, when reacted with the substrate 
molecules, act as the catalysts and can convert a colourless substrate to a 
coloured product which can be easily detected using a plate reader at a 
specific wavelength for this substrate. Many enzymes are used for ELISA 
labelling and Table 6.1 lists some examples of the most commonly used 
enzymes and their corresponding substrates. 
 
Table 6.1 The most commonly used enzymes in ELISA and their substrates  
     
Enzymes Substrates 
 
  Horse Radish Peroxidase 
             
            3,3’,5,5’-Tetramethylbenzidine (TMB) 
            ortho-phenylenediamine dihydrochloride (OPD) 
 
Alkaline Phosphatase                 p-N itrophenyl Phosphate (pNPP) 
Beta-Galactosidase              o-nitrophenyl-β-D-Galactoside (ONPG) 
                            
 
74 
 
Several different types of ELISA have been developed and studies that 
mostly differ in the sequence of addition of antigens or antibodies to the 
solid plate: 
Direct ELISA 
Indirect ELISA 
Competitive ELISA 
Sandwich ELISA 
 
The indirect ELISA technique used during this study requires the addition of a 
primary antibody that will bind to antigen molecules adsorbed on to the plate. 
The binding of these two molecules can then be recognized by an enzyme-
labelled secondary antibody, which will then convert a specific substrate to a 
coloured product to be measured (Figure 6.1). 
 
Figure 6.1 Indirect ELISA technique (source: Gong, 2009) 
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The aim of using the ELISA technique is to enable quantitative measurement 
of the effects of honey treatment on the number of viral antigen present in a 
sample. It is hypothesised that honey treated samples will contain less of the 
antigen compared to untreated samples. 
 
6.2 Experiments 
6.2.1 Determining optimal dilutions of primary antibody 
6.2.1.1 Materials and Methods 
A549 cells were grown in ten of the wells on a 24-well cell culture plate 
overnight as described in Section 3.2.4. Once confluent, growth medium was 
removed via aspiration. Viral stock suspension (200 μl) was added to five of 
the wells, while the other five remained uninfected to serve as controls. The 
plate was then put in a 5% CO2 incubator set at 37°C for one hour. After one 
hour, the supernatant was aspirated off and all wells supplemented with 1 
ml maintenance medium. The plate was then incubated and observed daily 
for CPE development. Once the infected cells had reached a CPE score of 3, 
the medium was removed and each well was washed once with wash buffer 
(0.05% Tween 20 in PBS pH 7.3 (see Section 3.2.6)).  The cells were then fixed 
with 80% acetone for 10 minutes, and air dried. Once dry, the cells were 
treated to destroy any endogenous peroxidase activity present. This was 
done by adding 1 ml of solution containing 3% hydrogen peroxide in 
methanol and incubating the plate at 37°C for one hour. After one hour, the 
solution was aspirated off and the cells were washed once with wash buffer. 
Blocking buffer (1% bovine serum albumin (BSA) from Sigma prepared in 
PBS pH 7.3) was then added to each well in 200 µl aliquots and the plate was 
incubated at 37°C for 30 minutes.  After incubation with the blocking buffer, 
the wells were washed 3 times with wash buffer and air dried. The primary 
antibody used in this experiment, Mouse Anti-Respiratory Syncytial Virus 
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monoclonal antibody (1 mg/ml, Millipore, Catalog no. MAB8262, Lot no. 
LV1700732) was prepared in PBS (pH 7.3) and 0.05% Tween 20 and diluted 
to various concentrations. They were then added in 200 µl aliquots to each 
well. The concentrations used were 10 µg/ml, 5 µg/ml, 2.5 µg/ml, 1.25 µg/ml, 
0.625 µg/ml. The plate was then incubated at 37°C for 1 hour.  After 
incubation with the primary antibody, the wells were washed 3 times with 
wash buffer for 5 minutes each time, then 200 µl of the stock secondary 
antibody solution (Goat anti-mouse IgG, HRP conjugate polyclonal antibody 
from Millipore, Catalog no. 12-349, Lot no. DAM 1698735) (1 mg/ml) 
rehydrated in PBS (pH 7.3) was added to each well (using a dilution of 
1:10,000 as suggested by manufacturer) and incubated at 37°C for 1 hour.  
After incubation with the secondary antibody, the wells were washed 3 
times with wash buffer for 5 minutes each time.  During the last wash the 
substrate was prepared by mixing 30 ml of substrate buffer (3.73 g citric acid 
and 5.04 g di-sodium hydrogen phosphate made up to 400 ml water, pH 5) 
with a 30 mg Ortho-phenylenediamine dihydrochloride (OPD) tablet 
(Sigma). Once the tablet had dissolved, 200 µl of 6% H2O2 was added.  
Substrate was added to each well in 200 µl aliquots and incubated at 37° for 
30 minutes in the dark.   After incubation, 50 µl 2 mol/l H2SO4 was added to 
each well to stop the enzyme action.  The absorbance was then read at 
450 nm using a BMG FLUOstar Optima plate reader.   
 
6.2.1.2 Results 
The results of the assay determining the optimal dilutions of the primary 
antibody are shown in Fig 6.2. There was no decrease in absorbance readings 
observed with decreasing concentration of primary antibody for both the 
cells with no virus and cells infected with RSV. 
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Figure 6.2 Absorbance values recorded from an ELISA using various 
dilutions of the primary antibody with a 1:10 000 dilution of the secondary 
antibody 
 
 
 
6.2.1.3 Discussion 
Although the manufacturer’s instructions were followed, the absorbance 
readings were too low to provide any useful quantification of the antigen 
present (0–0.2). From the readings it was concluded that there was either a 
very small amount of viral antigen present on the plate, or that the 
secondary antibody was too dilute. A separate experiment was performed in 
which higher concentrations of secondary antibody were used with a 
primary antibody dilution of 1/200 (Section 6.2.2).  
 
6.2.2 Determining optimal dilution of secondary antibody  
6.2.2.1 Materials and Methods 
A549 cells were grown overnight in a 24-well plate as outlined in Section 
3.2.4. The method as described in Section 6.2.1.1 was used with the following 
changes: 200 µl of the primary antibody (prepared in PBS pH 7.3 and 0.05% 
Tween 20) was added to each well at a dilution of 1/200 (5 μg/ml) and 
incubated at 37°C for 1 hour.  After incubation with primary antibody, the 
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wells were washed 3 times with wash buffer for 5 minutes, and 200 µl of the 
secondary antibody prepared in PBS (1 mg/ml) was added to each well 
(using dilutions of 1/200, 1/400 and 1/800 and 1/1600) and incubated at 37°C 
for 1 hour.  The washing, enzyme reaction and reading of absorbance were 
carried out as in the preceding experiment (Section 6.2.1.1).   
 
6.2.2.2 Results 
The results from the assay determining optimal dilutions of the secondary 
antibody are shown in Figure 6.3. The absorbance readings were positively 
correlated to the secondary antibody dilution, and the RSV-infected cells 
gave much higher absorbance readings than the controls.  
 
Figure 6.3 Absorbance values from an ELISA using a 1:200 dilution of the 
primary antibody and various dilutions of the secondary antibody 
 
 
 
6.2.2.3 Discussion 
This experiment demonstrated that the previous problems encountered with 
the lack of signal were in fact due to the low concentration of secondary 
antibody used. Much higher concentrations were used in the experiment 
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of 1:10,000. Here a positive correlation between concentration of secondary 
antibody and absorbance reading can be seen, and the RSV-infected wells 
clearly exhibited higher absorbance readings. However, it is evident that 
there was some non-specific binding occurring between the secondary 
antibody and the plate as the negative controls also exhibited some colour 
change, with the absorbance readings also decreasing with lower 
concentrations of secondary antibody. For further experiments, the 
successful dilution of 1:200 of the primary antibody and 1:400 of the 
secondary antibody was used, with a longer incubation time with blocking 
buffer to minimise the non-specific binding. 
 
6.2.3 Further observations on the effect of honey 
6.2.3.1 Materials and methods 
A549 cells were grown overnight in a 24-well plate as outlined in Section 
3.2.4. Once confluent, cells were inoculated with RSV for 1 hour before the 
medium was replaced with 0% and 2% M117 honey and left in a 37°C, 5% 
CO2 incubator. Once the untreated cells (0% honey) had reached a CPE score 
of 3, the medium was removed and each well was washed once with wash 
buffer (0.05% Tween 20 in phosphate buffered saline (PBS) pH 7.3). The 
method as described in Section 6.2.2.1 was used with some changes.  
Blocking buffer was left on for 1 hour instead of 30 minutes. Primary 
antibody (prepared in PBS pH 7.3 and 0.05% Tween 20) was added to each 
well in 200 μl aliquots at a dilution of 1/200 (5 μg/ml) and incubated at 37°C 
for 1 hour.  After incubation with primary antibody, the wells were washed 3 
times with wash buffer and 200 µl of the secondary antibody prepared in 
PBS was added to each well (at a dilution of 1/400) and incubated at 37°C for 
1 hour.  The washing, enzyme reaction and reading of absorbance were 
carried out as described in Section 6.2.1.1. 
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6.2.3.2 Results 
The results from the assay measuring the effects of honey on the amount of 
detected viral antigens are presented in Figure 6.4.  
 
Figure 6.4 Means ± SEM of absorbance values obtained from ELISA detecting 
the amount of viral antigens present in controls and RSV-infected cells 
incubated with or without 2% M117 honey 
 
 
 
The absorbance readings obtained from RSV-infected cells were significantly 
higher than those recorded for RSV-infected cells treated with 2% M117 
honey. No differences were observed between the control cells. 
 
6.2.3.3 Discussion 
This experiment confirmed the results from the previous experiments 
observing CPE development that honey has an inhibitory effect on the 
development of RSV infection in A549 cells. It was shown in this study that 
RSV-infected cells which were treated with 2% M117 honey had a lower 
number of viral antigens detected compared with untreated cells. This 
suggests that honey somehow prevents viral replication, resulting in lower 
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numbers of viral particles and slower development of CPE which was 
observed in the previous experiments.  
 
How honey affects RSV replication remains unclear. It is possible that honey 
deactivates, or inhibits the viral particles from entering the cells, resulting in 
suppression of infection as observed in the earlier neutralisation 
experiments. Although less likely, another possibility is that the viral 
particles are entering the cells, but a cellular response elicited by honey may 
be inhibiting the transcription or translation of viral protein. An experiment 
looking at viral gene transcription in RSV-infected cells incubated with or 
without honey would be desirable as it would narrow down the stages of 
infection at which honey may be acting on the viral particles. Further studies 
on the effects of honey on the upregulation of genes involved in the antiviral 
response in A549 cells would also be of value.
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Chapter Seven  
          The effect of honey on RSV replication 
 
7.1 Initial experiments 
7.1.1 Introduction 
The aim of this chapter was to investigate the effect of honey on viral 
replication kinetics in RSV-infected cells. Findings from preceding chapters 
have confirmed a reduction in virus titres using ELISA, a method which 
detects the amount of viral antigen present in a sample, however, it was 
desirable to determine whether the effects of honey could also be observed at 
the transcription level, and to rule out the possibility of the occurrence of 
“abortive” replication, where there is an increase in the expression of viral 
transcripts and genome replication that does not lead to the production of 
detectable progeny virus (Boukhvalova et al., 2007). 
 
 Initial experiments look at cells that have been incubated with or without 
virus. They were performed as a way to validate the methods to be used, and 
to determine the specificity of the designed primers before performing 
further experiments looking at the treatment effect of honey. Conventional 
RT-PCR analysis was used to detect whether mRNA for specific genes of 
interest were present. This enabled a number of genes to be screened for 
further quantification with real-time PCR. 
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7.1.2 Materials and Methods 
7.1.2.1 Preparation of cells 
A549 cells were seeded into cell culture flasks and incubated at 37°C 
overnight as described in Section 3.2.4. Once confluent, the growth medium 
was removed from the cells. Viral stock suspension (1 ml) was added to one 
flask and the other served as a control. The flask was then put in a 5% CO2 
incubator set at 37°C for one hour. After one hour, the inoculum was 
aspirated off and replaced with 4 ml of maintenance medium. The flasks 
were then left to incubate and were observed daily for CPE development. 
 
7.1.2.2 Lysis of cells and RNA extraction 
Once a CPE score of 3 had been reached with the RSV-infected cells, the 
growth medium was poured off the flasks and 700 µl of 5 M guanidium 
thiocyanate (Roche) was added to each. The flasks were then rocked gently 
and left at room temperature for 5 minutes for further lysis. The lysed cells 
from each flask were then transferred into a 1.75 ml Eppendorf 
microcentrifuge tube and 75 µl of 2 mol/l sodium acetate buffer (pH 4.0) was 
added. The tube was inverted to mix the contents before adding 750 µl of 
water-saturated phenol. The contents were mixed and the tube left for 5 
minutes at room temperature. After 5 minutes, 200 µl of chloroform was 
added and the tube was vortexed for 20 seconds and then left on ice for 10 
minutes. 
 
After 10 minutes on ice, the tube was then centrifuged for 15 minutes at 
16 000 rpm at 4°C using an Eppendorf bench microcentrifuge. The clear 
supernatant containing the RNA was then transferred to a new tube and the 
process repeated from the addition of 75 µl of 2M Sodium Acetate. After the 
tube had been centrifuged for 15 minutes for the second time, the clear 
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supernatant was again transferred to a new tube and an equal volume of 
isopropanol was added. The tube was inverted to mix the contents and then 
was stored at room temperature for 20 minutes to precipitate the RNA.  
 
After 20 minutes, the tube was centrifuged for 10 minutes at 16 000 rpm at 
4°C in a bench centrifuge. The supernatant was then removed carefully, 
avoiding touching or moving the pellet. Ethanol (1 ml of 70% ethanol) was 
added to the tube which was then mixed briefly and centrifuged for 4 
minutes at 7 500 rpm at 4°C.  The tube was then taken out of the centrifuge 
and the ethanol removed carefully, avoiding the RNA pellet. The tube was 
briefly re-spun for 5 seconds to bring down any remaining ethanol which 
was then also aspirated off. The tube was then left open on the bench to air-
dry the RNA pellet for about 5 minutes before adding 20 µl of 1 X Tris MnCl2 
buffer (10 mmol/l Tris, 0.5 mmol/l MnCl2, pH 7.8). The tube was vortexed to 
re-dissolve the pellet prior to addition of 1 µl of DNAse (Promega) to remove 
any residual DNA. The tube was then incubated for 30 min in a thermomixer 
(37°C). The DNAse was then inactivated by adding 1 µl of DNAse Stop 
Solution (Promega) and the tube incubated for 10 min at 65°C in a 
thermomixer. RNA quality was analysed and the sample frozen at -80°C 
until required.  
 
7.1.2.3 Checking RNA quality 
 To check the quality of the extracted RNA, 5 µl of RNA from each tube was 
run in a 1% agarose gel (see Section 7.1.2.4) in 1X SB buffer (5.6 g boric acid, 
1 g NaOH made up to 2 litres with distilled water, pH 8.5). The samples 
electrophoretically separated at 70 volts for 60 minutes and the gel was 
viewed under UV light. RNA integrity was indicated by the presence of 
sharp, clear 28S and 18S rRNA bands. Partially degraded RNA and primer 
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dimers would appear as a low molecular weight smear. RNA purity was 
checked by measuring the absorbance ratio of samples at 260 nm/ 280 nm 
(A260/A280) using a NanoDrop ND-1000 Spectrophotometer. Values of 1.8– 2.0 
were considered acceptable. 
 
7.1.2.4 Preparation of a 1% agarose gel 
Agarose (0.3 g) was added to 30 ml 1 X SB buffer and microwaved on high 
for 2 minutes. Once the agarose was dissolved, the flask was cooled by 
swirling the flask, and 2 µl of ethidium bromide (10 mg/ml stock solution) 
was added. Approximately 30 ml was poured into a gel caster 
(Horizon11.14, GibcoBRL), an eight lane comb was added, and the gel was 
left to set for around 30 minutes. For 2% agarose gels, 0.6 g of agarose was 
added to 30 ml 1 X SB buffer and prepared in the same manner. 
 
7.1.2.5 First-strand cDNA synthesis 
After extraction of purified RNA (as described in Section 7.1.2.2), cDNA was 
prepared from this for conventional RT-PCR according to a method adapted 
from Jobin et al. (1998) and Bierhaus et al. (1997). For each cell sample, 3 µl of 
RNA sample was placed in a 1.5 ml Eppendorf tube along with 1 µl random 
hexamers (Bio-Rad Laboratories) and 4 µl DEPC-treated water. Random 
hexamers are used to ensure the efficient amplification of all RNA in a 
sample. The contents were mixed by vortex. The tubes were then incubated 
for 5 min at 70C in a PCR machine (MJ Research PTC-200 Peltier Thermal 
Cycler) to separate secondary structures from the RNA. The tubes were then 
put on ice for 10 min to enable the random hexamers to anneal to single-
stranded RNA. 
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In a separate 1.5 ml Eppendorf tube, 4 µl of 5 X First Strand Reverse 
Transcriptase buffer (Invitrogen) was placed with 1 µl of 0.1 mol/l DTT 
(Invitrogen) along with 1 µl of dNTP mix (Invitrogen, 10 mmol/l each), 3 µl 
DEPC-treated water and 1 μl Superscript III Reverse Transcriptase™ 
(Invitrogen). The contents of this tube were added to the tube containing the 
RNA and random hexamer mix. The samples were then incubated in a PCR 
machine at 25°C for 10 minutes, 50°C for 60 minutes and the reaction was 
terminated at 85°C for 5 minutes. The cDNA samples were then stored at 
-80°C until required.  
 
7.1.2.6 Primers 
Primer pairs for the RSV genes investigated were designed using the Primer3 
version 0.4.0 (Rozen & Skaletsky, 2000) software and are listed in Table 7.1. 
 
Table 7.1 Primer sequences for RSV F, M, L and NS1 genes and housekeeping 
gene (GAPDH) 
 
Gene 
Primer sequence (forward and reverse) 
5’-3’ 
Primer 
(bp) 
Product 
(bp) 
Tm 
(°C) 
F CAAGAACCGACAGAGGATGG 
GCATGACACAATGGCTCCTA 
 
20 
20 
245 64.6 
63.7 
M ATGGGGCAAATATGGAAACA 
AGGTCCATTGGGTGTGGATA 
 
20 
20 
214 63.7 
64.0 
      L AAAGGTTACGGCAGAGCAAA 
TTAACAACCCAAGGGCAAAC 
 
20 
20 
246 63.5 
63.5 
NS1 ATGGGGTGCAATTCACTGAG 
CAGGGCACACTTCACTGCT 
 
20 
19 
202 64.9 
64.2 
GAPDH GAGTCAACGGATTTGGTCGT 
TTGATTTTGGAGGGATCTCG 
20 
20 
238 63.9 
63.8 
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A primer pair for the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used based on previous publications 
(Parekkadan et al., 2007; Ylösmäki et al., 2008). All primers were purchased 
from Sigma-Aldrich. 
 
7.1.2.7 PCR with iStarTaq 
The PCR process involves multiple cycles of template denaturation, primer 
annealing, and primer elongation to amplify DNA sequences. iStar Taq 
DNA polymerase (Intron Biotechnologies) was used for PCR amplifications. 
An antibody complexed to Taq polymerase acts to block polymerase activity 
until after the first 94C denaturation step during PCR cycling. Each PCR 
reaction contained 20 µl of Master Mix, 0.5 µl of forward and 0.5 µl of 
reverse primers, 1 µl cDNA and 1 µl DNA polymerase.  
 
After pre-incubation for 2 min at 94C (MJ Research PTC-200 Peltier Thermal 
Cycler), the target DNA was amplified with 40 cycles, each cycle consisting 
of a denaturation step at 94C (20 sec melting), annealing for 20 sec at 60C 
(optimised for the specific genes, as presented in Table 7.1), and extension at 
68C for 35 sec.  
 
7.1.2.8 Electrophoresis of DNA 
To check whether the cDNA had been successfully synthesised, a 2% agarose 
gel was prepared (Section 7.1.2.4) and run containing 5 µl of amplified cDNA 
mixed with 2 µl of loading buffer (40% sucrose, 0.25% bromophenol blue, 
0.25% xylene cyanol) for each sample. A 100 bp DNA ladder (Invitrogen) 
was also loaded on each gel to enable the base pair size of the DNA products 
to be determined. Electrophoresis was carried out in Horizon tanks 
(Invitrogen) containing SB (1 X) buffer, at 110 volts for approximately 25 
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minutes until separation was achieved. DNA was illuminated using UV, 
photographed and analysed using the Scion Image software. 
 
7.1.2.9 DNA sequencing 
The PCR products from the initial experiments were sent to the Waikato 
DNA Sequencing Facility for validation. To prepare the samples for 
sequencing, the products had to be purified. This was performed by adding 
40 µl of each PCR product into a 1.7 ml Eppendorf tube containing 40 µl of 
20% polyethylene glycol (PEG) solution and vortexing the tube before 
leaving at room temperature for 15 minutes. The tube was then vortexed 
again and centrifuged at 16 000 rpm for 10 minutes. The supernatant was 
aspirated off and 1 ml 100% ethanol added to the remaining pellet. The tube 
was vortexed and centrifuged again for 5 minutes. The ethanol was aspirated 
off and replaced with 1 ml 70% ethanol, and the tube centrifuged for 5 
minutes. All remaining liquid was aspirated off and the tubes left to air dry. 
Once dry, 15 µl of TE buffer (10 mmol/l Tris pH 8, 1 mmol/l EDTA, pH8) was 
added and the amount and quality of the products checked with the 
NanoDrop ND-1000 Spectrophotometer. Primers were diluted to 5 pmol/l 
and were also sent away with the templates for sequencing. 
 
7.1.3 Results and Discussion 
Figure 7.1 shows the gel electrophoresis run of PCR products acquired from 
cells that have been incubated with or without RSV. A 100 bp ladder was 
included as a guide to determine whether the products observed are of the 
correct size (based on Table 7.1). Clear bands were seen for the housekeeping 
gene in both infected and uninfected cells. 
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Figure 7.1 2% agarose gel of PCR products. 
(From left: 100 bp ladder, F, M, L, N and GAPDH from RSV-negative cells and               
F, M, L, N and GAPDH from RSV-positive cells) 
 
 
 
Clear bands representing the PCR products from RSV-infected cells for RSV 
genes F, M and L can also be seen. There was no clear band observed for the 
RSV N gene in the infected cells and this was therefore excluded from 
further experiments. There was also some non-specific binding of primers 
seen in the uninfected cells, as illustrated by the presence of faint bands and 
smearing, which was minimised in further experiments by raising the 
melting temperature from 55°C to 60°C. 
 
7.2 Quantitative Real-Time RT-PCR 
7.2.1 Introduction 
Real-time PCR was used to provide a quantitative measure of the 
transcription of mRNA for specific proteins of interest. A fluorescent marker 
is hybridised to the cDNA between two PCR primers for a single gene of 
interest. As PCR proceeds, the 5’ nuclease activity of the Taq polymerase 
cleaves the probe, releasing the tag such that the fluorescence is proportional 
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to the amount of cDNA present. SYTO82 (Roche) was used as a fluorescent 
marker allowing any double-stranded DNA generated during PCR to be 
detected. Specificity of the PCR products was confirmed by melt curve 
analysis and electrophoresis on a 2% agarose gel. 
 
7.2.2 Materials and Methods 
After extraction of purified RNA (as described in Section 7.1.2.2), it was 
prepared for real-time PCR according to a method adapted by Dr Ray 
Cursons (University of Waikato) from that described by Konnai et al. (2003). 
All steps prior to the addition of cDNA were carried out in a PCR cabinet. 
 
Real-time qPCR was performed using a Corbett Research qPCR machine, 
including fluorescent emission and detection of the signals. Reactions were 
carried out in a total volume of 20 μl. A stock master mix solution was made 
which contained (for 10 ml); 1 ml 10X buffer (500 mmol/l KCl, 100 mmol/l 
Tris HCl (pH 9.0 at 25°C), 15 mmol/l MgCl2, and 1% Triton X-100), 2 ml 
MgCl2 (25 mmol/l), 7 ml distilled water, 20 µl of each dNTP (10 mmol/l) and 
4 µl SYTO82 nucleic acid stain (Invitrogen). This stock solution was 
distributed into 1.5 ml Eppendorf tubes and each tube was treated with 10 µl 
of DNAse for 1 hour. The DNAse was then inactivated by heating the tubes 
at 75°C for 10 minutes in a thermomixer. Each real-time PCR reaction 
mixture contained 18.6 µl master mix, 0.13 µl each of the forward and 
reverse primers, 0.15 µl of Taq DNA polymerase and 1 µl of cDNA. Each 
sample was tested in duplicate, and the experiment was repeated twice on 
different days. 
 
The qPCR protocol using Corbett Rotor-Gene 6000 (Corbett Life Science, NZ 
Ltd) consisted of pre-incubation for 2 min at 95C followed by amplification 
of target cDNA with 40 cycles, each cycle consisting of a denaturation step at 
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95C for 20 sec, annealing for 20 sec at 60C, extension at 68C for 30 sec, and 
determination of fluorescence at 80C for 10 sec. The annealing temperature 
was raised to 60°C from 55°C as previously used in order to minimise the 
presence of non-specific products. To check if there was any contamination 
with genomic DNA, a negative control was done for every reaction set by 
performing the RT-PCR reaction with sterile water instead of cDNA. 
 
Melting curve analysis was performed which resulted in single 
product-specific melting temperatures above 80C for each primer pair, 
confirming specificity of each primer pair. The samples were analysed for 
both the target genes and an endogenous control gene, GAPDH. The 
expression levels of the target genes were reported relative to the expression 
levels of GAPDH using the comparative quantitation method in the Rotor-
gene 6000 software. It is recognised that housekeeping genes are 
differentially expressed under various experimental conditions (Rogler et al., 
2004). 
 
After analysis of the real-time PCR results, an end-product sample of DNA 
from the reaction for each gene was analysed by 2% agarose gel 
electrophoresis (as described in Section 7.1.2.8). This enabled the presence of 
any DNA contamination to be seen and the size of the products to be 
determined by comparison with a 100 bp ladder. The agarose gel was 
prepared as described in Section 7.1.2.4.   
 
Student’s t-test was used for statistical analysis. 
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7.2.3 Results 
The results from the qPCR experiments are shown in Figure 7.2.  
 
Figure 7.2 Expression of viral genes in RSV-infected cells that have been 
treated with or without 2% M117 honey. 
 
 
 
This graph shows the expression of viral genes in non-treated and treated 
samples normalised to GAPDH. Significant differences in detected levels of F 
gene and M gene transcripts were observed, however, there was no 
significant difference in the levels of L gene transcripts detected. Correct 
products and presence of contamination were checked by melt curve 
analysis and gel electrophoresis. A representative gel is shown on Figure 7.3. 
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Figure 7.3 A representative gel showing PCR products from controls and 
RSV-infected cells incubated with or without 2% M117 honey. 
a) cells only, b) cells in 2 % honey, c) RSV-infected cells, d) RSV-infected cells 
treated with 2% honey 
 
 
7.2.4 Discussion 
A reduction in the number of viral antigens present in RSV-infected cells 
treated with honey has been previously shown in the ELISA experiments in 
Chapter 6. This chapter, in turn, has illustrated that not only has honey 
inhibited the replication of RSV at the translation level, as shown by the 
amount of protein detected in the previous ELISA experiments, but also at 
the transcription level, as demonstrated by the reduced number of viral 
mRNA detected in the treated samples in this experiment. Significant 
differences were observed in the levels of F and M gene transcripts detected. 
No significant differences were found between the amount of L gene 
transcripts acquired from treated and untreated samples, however this could 
be a reflection on the small sample number. A greater number of repeats of 
this experiment are needed to confirm the findings presented here.  
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The results from this study support the hypothesis that honey acts on the 
virus particle directly by either preventing its entry into the cell or inhibiting 
its replication within the cell. In future studies, it would be of value to 
monitor the transcription of all RSV genes from the start of infection and 
follow its progress in honey-treated and untreated cells. It would also be of 
importance to perform similar experiments on cellular genes involved in the 
antiviral response, to determine what role they play in this inhibition and 
how honey affects them.  
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Chapter Eight  
   Determining the antiviral component in honey 
 
8.1 Testing the antiviral activity of the sugar content of honey 
8.1.1 Introduction 
This experiment aimed to test whether the sugar content of honey is 
responsible for the slowing of the rate of CPE development caused by RSV 
when cells are treated with honey, as shown in Chapter 4. The same method 
was used as described in Section 4.2.2c, with artificial honey used instead of 
natural honey. Manuka honey M117 was also used as a control. 
 
8.1.2 Materials and Methods 
Artificial honey was made according to a recipe described by White (1975a), 
which was formulated using the average composition of at least 400 samples 
of major commercial honey types in the USA. It contained 17.2% water, 
38.4% fructose, 30.3% glucose, 1.3% sucrose, 8.6% maltose and 1.4% 
maltodextrin at neutral pH. The syrup was stored at 4°C and solutions were 
made up as described for natural honey in previous chapters. 
 
A549 cells were seeded into 24-well plates and incubated at 37°C overnight 
as described in Section 3.2.4. Once the cells were confluent, growth medium 
was removed from the cells. Viral stock suspension (200 μl) was added to 
each well and left to incubate at 37°C (5% CO2) for 1 hour. After one hour, 
the inoculum was aspirated off and replaced with 1 ml of maintenance 
medium containing varying concentrations of either M117 honey or artificial 
honey. The plate was then incubated at 37°C (5% CO2) and observed daily 
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for CPE development. The experiment was performed in triplicate within 
one plate and was repeated, again in triplicate, on a different day. 
 
8.1.3 Results 
The results of the experiment investigating the antiviral effects of artificial 
honey are presented as plots of developing CPE in Figure 8.1.   
 
Figure 8.1 CPE development in RSV-infected A549 cells incubated with 
varying concentrations of honey and artificial honey 
The results are presented as mean ± SEM of triplicates for each of the two days of 
experiments. 
 
 
 
The controls of each honey and artificial honey concentration without virus 
were shown to not cause morphological changes of the cells over the 
observation period.   
 
8.1.4 Discussion 
This experiment aimed to determine if artificial sugar, at concentrations 
equivalent to that found in 2% natural honey, would have any antiviral 
activity against RSV. The results obtained demonstrate that artificial sugar 
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by itself has no detectable effect on the development of CPE caused by RSV 
in A549 cells. The development of CPE in cells treated with 1% and 2% 
artificial honey was similar to that observed in non-treated cells, and much 
faster than in cells treated with 1% and 2% Manuka honey. Although it can 
be concluded from this experiment that the sugars in honey alone do not 
have any antiviral effects, it is possible that they have a role to play in the 
overall observed antiviral activity when combined with other components 
found in whole honey.   Future experiments would need to confirm this. 
 
8.2 Testing the antiviral activity of hydrogen peroxide in honey 
8.2.1 Introduction 
An enzyme within honey, glucose oxidase, produces hydrogen peroxide 
when honey is diluted. Hydrogen peroxide is a well known and widely used 
antiseptic, and although present in small quantities in diluted honey, it is 
possible that it plays a role in the antiviral activity exhibited in previous 
experiments.   
 
Tests were therefore performed to test the antiviral activity of diluted honey 
and diluted honey with catalase, an enzyme which functions to catalyze the 
decomposition of hydrogen peroxide to water and oxygen. This experiment 
aimed to determine whether the antiviral effect of honey was solely or partly 
due to the presence of hydrogen peroxide upon dilution. A honey was used 
which had a high level of production of hydrogen peroxide. 
 
8.2.2 Materials and Methods 
Confluent A549 cells were prepared as described in Section 3.2.4.  Bovine 
liver catalase (Sigma) was made to 2 mg/ml in maintenance media and was 
filter sterilised.  A solution of 4% Rewarewa (RE32) honey was prepared in 
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maintenance medium. The 4% honey solution was diluted down to 2% 
honey by mixing with the catalase solution, then filter-sterilised. Once 
confluent, the growth medium was aspirated off the cells which were 
inoculated with 200 μl viral stock for 1 hour at 37°C (5% CO2). The viral 
solution was then removed and replaced with 1 ml of maintenance medium 
containing either honey or honey mixed with catalase. Medium without 
honey or catalase was included as a control.  
 
8.2.3 Results and Discussion 
Despite filter-sterilisation of all materials used on the cells for this 
experiment, what seemed to be a bacterial contaminant remained persistent 
in all catalase-containing media. No results were therefore acquired from this 
experiment due to time constraints. Future studies should include this 
experiment to determine the role hydrogen peroxide plays in the observed 
antiviral activity of whole honey.       
 
8.3 Testing the antiviral activity of methylglyoxal 
8.3.1 Introduction 
It was found in earlier experiments that the Manuka honeys tested generally 
had higher antiviral activity compared with the other honeys tested. Manuka 
honey is known to contain high levels of methylglyoxal (Adams et al., 2008). 
Although a previous study by Littlejohn (2009) found that methylglyoxal at 
concentrations found in 5% and 10% honey had no effect on CPE 
development caused by adenovirus and herpes simplex virus, it was 
desirable to examine its effects on RSV. The aim of this experiment was to 
use methylglyoxal, in similar levels found in 2% honey, in a neutralisation 
assay, in order to determine whether methylglyoxal is wholly or partly 
responsible for the observed antiviral effects of whole honey on RSV.  
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The effect of methylglyoxal alone on the cell line was first tested to 
determine if there was any cytotoxic effect. This was performed both visually 
and by performing an MTT assay, a technique used to measure the activity 
of enzymes, found in living cells, that reduce MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide). These reactions only take place when 
reductase enzymes from the cells are active, therefore, the conversion is used 
as to measure the number of viable cells present in a treated sample. 
 
8.3.2 Materials and Methods 
a) MTT assay 
A549 cells were grown overnight in 24-well plates as described in Section 
3.2.4. A stock solution of methylglyoxal was made by diluting commercially 
available 40% methylglyoxal (5 500 mmol/l) solution (Sigma Aldrich) by 
1:10,000 in maintenance medium. This was to create a stock solution that, 
when diluted, will reach methylglyoxal concentrations around and including 
that found in 2% whole high-activity manuka honey (~0.2 mmol/l) 
(Littlejohn, 2009). From the stock solution (0.55 mmol/l), solutions of 
methylglyoxal at concentrations of 0.4, 0.3, 0.2 and 0.1 mmol/l were made. 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
solution (5 mg/ml) was made by adding 125 mg of MTT salt (Sigma) to 25 ml 
sterile PBS (see Section 3.2.6). The solution was then sterilised by filtration 
and stored at 4°C. Lysing buffer was prepared by dissolving 10 g sodium 
dodecyl sulfate (SDS) in 20 ml distilled water, 20 ml dimethylformamide 
(DMF) and 1 ml acetic acid to reach a pH of 4.7.  
 
Once the cells were confluent, growth medium was replaced with various 
concentrations of methylglyoxal and incubated at 37°C for 1 hour. After 1 
hour, the methylglyoxal was removed and the cells were washed once with 
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PBS (pH 7.3).  MTT solution (125 µl) was added to each well including 
control wells and the plate was incubated for 2 hours at 37°C, 5% CO2. After 
2 hours, the supernatant was removed and 1 ml of lysing solution was 
added. The plate was left at 37°C in a 5% CO2 incubator overnight. The 
following day, the absorbance (at 600 nm) of the wells was measured in a 
BMG Fluostar Optima plate reader using the lysing solution as the blank. 
The experiment was repeated twice on different days. Student’s t-test was 
used for statistical analysis. 
 
b) Methylglyoxal neutralisation assay 
A549 cells were grown overnight in 24-well plates as described in Section 
3.2.4. A stock solution of methylglyoxal was made by diluting 40% 
methylglyoxal solution by 1:10 000 in maintenance medium. From the stock 
solution, solutions of methylglyoxal at concentrations of 0.4, 0.3, 0.2 and 0.1 
mmol/l were made. Viral supernatant (200 μl) was added to 800 μl of 
methylglyoxal solution of various concentrations in Eppendorf 
microcentrifuge tubes which were then placed in a shaking incubator (Level 
1, 37°C) for one hour. After one hour, growth medium was aspirated off the 
cells and replaced with 1 ml of each of the solutions of methylglyoxal with 
virus and left for 1 hour in the 37°C, 5% CO2 incubator to inoculate. After 
inoculation, the supernatant was removed and replaced with maintenance 
medium, and the plate returned in the incubator. Daily observations were 
made and the development of CPE was recorded until a high level of CPE 
had developed with the untreated virus. The experiment was conducted in 
triplicate and repeated in triplicate on a different day. 
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8.3.3 Results 
The results from the MTT assay looking at the effects of methylglyoxal on 
cell viability are shown on Figure 8.2.  
 
Figure 8.2 Effect of methylglyoxal on the viability of A549 cells. 
The absorbance recorded from an MTT assay performed on cells incubated with or 
without methylglyoxal for one hour is shown as mean values ± SEM. 
 
 
 
No significant differences in absorbance values were found in MGO-treated 
cells compared with the controls. The results from the methylglyoxal 
neutralisation assay are shown in Figure 8.3.  
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Figure 8.3 Effects of pre-treatment of RSV with methylglyoxal on the 
development of CPE in A549 cells 
The CPE score is shown for successive days of incubation of cells infected with RSV 
that had been previously treated with varying concentrations of methylglyoxal for 1 
hour. The graph represents the means ± SEM of all replicates and repeats. 
 
 
 
All triplicates and repeats for the neutralisation assay gave identical results 
and demonstrated the inhibitory activity of methylglyoxal against RSV. By 
Day 5, it was observed that RSV-infected cells without methylglyoxal had 
reached a CPE score of 5, while RSV-infected cells treated with 
methylglyoxal at concentrations as low as 0.1 mmol/l only had a CPE score of 
1.  
 
8.3.4 Discussion 
This experiment has shown that methylglyoxal, even at low concentrations, 
had antiviral properties against RSV. By Day 5, cells inoculated with RSV 
that had been incubated with medium only had reached a CPE of 5 while the 
other cells inoculated with RSV that had been treated with various 
concentrations of methylglyoxal ranging from 0.1 mmol/l to 0.55 mmol/l had 
by this stage developed a CPE score of only 1. Methylglyoxal used at 2 
mmol/l has been shown to reduce the TCID of influenza virus by 50% 
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(Tiffany et al., 1957), however, findings from a study by Littlejohn (2009), 
where methylglyoxal at concentrations of 0.11 to 2.4 mmol/l was unable to 
suppress the development of CPE in adenovirus and had little effect on 
herpes simplex virus. So although methylglyoxal is an effective antiviral 
agent, it appears as though different strains and types of viruses vary 
significantly in their reaction to the substance.  
 
The finding that methylglyoxal is an effective antiviral agent against RSV 
may explain the greater activity seen previously in manuka honeys 
compared with other honeys, as these contain varying levels of 
methylglyoxal. It must be noted, however, that it is not likely to be wholly 
responsible for this observed activity, as other honeys which do not contain 
methylglyoxal (such as Honeydew and Rewarewa) also have antiviral 
properties.  
 
It would be of great importance in future studies to test the other 
components found in non-manuka honeys, such as antioxidants and 
phenolics, for their neutralising capabilities. 
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Chapter Nine  
General discussion and recommendations for 
future research 
 
9.1 Summary and General Discussion 
The effects of honey on respiratory syncytial virus were investigated in the 
preceding chapters of this thesis. In Chapter 4, it was found that honey had 
an inhibitory effect on the development of CPE caused by RSV in A549 cells, 
except in the protection experiment (Section 4.3), where culturing the cells in 
honey failed to slow down the subsequent progression of viral infection. 
Previous studies have shown that honey (0.000025 – 0.1%) can cause changes 
in gene expression in cells, such as upregulation of a wide range of 
mediators including TNF-α, IL-1β, and TGF-β (Harcourt, 2005). TNF-α in 
particular is thought to be important in the host response to viral infection ‐ a 
study looking at the effect of TNF-α treatment on HEp-2 cells before RSV 
infection showed that pre-treatment of the cells with TNF-α inhibited RSV 
replication as determined by CPE (Neuzil et al., 1996). RSV-infected BALB/c 
mice treated with antibody to TNF-α also had greater maximal weight loss 
and slower recovery time than control mice, further suggesting a protective 
role for TNF-α in RSV infection (Neuzil et al., 1996). Although no direct effect 
of honey on the cells were visually observed in this experiment, they cannot 
be ruled out until further investigations are conducted. It is possible that the 
washing away of the honey prior to adding the virus could have allowed 
diffusion of the protective component of honey, though this is unlikely in the 
period between aspiration of the honey solution and addition of virus (~ 2 
minutes).  
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As there is strong evidence of honey being able to  cause upregulation of 
genes in other types of cells (Harcourt, 2005), future studies should include 
determining the effects of honey on the expression of TNF-α and other genes 
involved in the host antiviral response such as type 1 interferons (Muller et 
al., 1994) and Toll-like receptors (Bowie & Haga, 2005) in A549 cells.  
  
The progression of infection in cells inoculated with RSV that had been pre-
treated with honey (Section 4.4) showed similar rates of CPE development as 
in a previous experiment looking at the inhibitory properties of honey 
(Section 4.2), indicating that either the honey is acting on the virus particle 
directly or that the honey present in the inoculum may be having an effect on 
the cells, despite the cells only being in contact with the honey (present in the 
inoculum) for one hour. There was no feasible method available to enable the 
separation of the viral particles from the honey solution. To confirm the 
neutralising activity of honey, any effects on the cells as a result of being 
incubated with honey for one hour must be determined. This could be done 
by performing timed qPCR experiments on cells that have been treated with 
honey for one hour, again looking at genes involved in the host antiviral 
response. Based on the results acquired from these experiments, it is unlikely 
that honey would be an effective prophylactic agent for individuals at risk of 
RSV infection, however, as discussed, further investigations are required to 
confirm this. In contrast, addition of honey to moderately infected cells was 
observed to halt the progression of infection, thus showing the potential 
benefit of using honey as a treatment in individuals already experiencing 
symptoms of infection.  
 
In Chapter 5, experiments testing the antiviral effect of a range of honey 
types demonstrated significant differences which somehow correlated to 
their phytochemical profiles and antibacterial activity. The Manuka honeys 
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were found to have the greatest antiviral effect, with the high-NPA honeys 
causing the greatest inhibition. The Rewarewa and Honeydew honeys 
showed inhibitory effects comparable to M115, a mid-range UMF honey. The 
Rewarewa honey and the Honeydew honey used both had a high level of 
antibacterial activity due to hydrogen peroxide, high iron-binding 
antioxidant activity and phenolics. In Chapter 8, it was shown that sugar, in 
similar levels found in 2% natural honey, is not an effective antiviral agent. 
In contrast, further investigations determined that methylglyoxal had potent 
antiviral activity even at very low concentrations, and may therefore be the 
component responsible for the greater inhibition seen in the high-NPA 
honeys. The component or components responsible for the observed effect in 
non-Manuka honeys are yet to be confirmed but is possible that a number of 
factors determine the level of antiviral activity a particular type of honey 
may have. Antioxidants, in particular, have been researched thoroughly over 
the years for their antiviral activity against a wide range of viruses and have 
been proven to be effective against them. Resveratrol (Faith et al., 2006), 
glutathione (Tian et al., 2010) and cinnamaldehyde (Ding et al., 2010) in 
particular have been associated with the suppression of NF-κB, thereby 
inhibiting viral replication of herpes simplex virus, dengue virus and 
coxsackievirus B3, respectively. Phenolics have also been shown to have 
some antiviral activity. One study evaluated the ability of (-)Epigallocatechin 
gallate (EGCg) and theaflavin digallate (TF3) to inhibit the infectivity of both 
influenza A virus and influenza B virus in Madin-Darby canine kidney 
(MDCK) cells in vitro (Nakayama et al., 1993). Study by electron microscopy 
revealed that EGCg and TF3 agglutinated influenza viruses, and that they 
prevented the viruses from adsorbing to MDCK cells. EGCg and TF3 also 
more weakly inhibited adsorption of the viruses to MDCK cells and 
inhibited haemagglutination by the influenza viruses (Nakayama et al., 
1993). Another study showed that semi-synthetic catechin derivatives 
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exerted inhibitory effects for all six influenza subtypes tested, as well as 
H2N2 and H9N2 avian influenza virus. The compounds strongly inhibited 
adsorption of the viruses on red blood cells and also restricted the growth of 
avian influenza virus in ovo (Song et al., 2007). 
 
Chapter 6 of the current study confirmed using ELISA, a quantitative assay, 
the observed treatment effects of honey. This reinforced the qualitative 
observations made in the preceding chapters. This was a necessary measure 
to eliminate any bias that may have occurred during the subjective scoring of 
CPE in these experiments. This experiment enabled statistical analysis of the 
quantitative data acquired, showed significant differences between 
honeytreated and untreated samples, and also provided some insight into 
the mechanism of action of honey by showing that treatment with honey 
resulted in a decrease of viral proteins produced. The qPCR experiments in 
Chapter 7 confirmed this, and demonstrated that the decrease in viral 
proteins produced stemmed from a decrease or inhibition in the 
transcription of viral genes. Future experiments could benefit from using the 
ELISA to track and compare the increase in viral titre in honey-treated and 
untreated samples from the point of inoculation over the course of a few 
days. It must be noted, however, that a limitation to this suggestion is the 
fact that at severe CPE levels, cells begin to detach from the plate surface, 
making performing an ELISA on severely infected cells an unreliable tool for 
measuring the amount of viral antigen present. Experiments could be 
performed on the combined supernatant and cells instead. They could also 
be performed using qPCR, to gain more information on the transcription of 
viral genes over the course of the experiment.  
 
Overall, this study has shown that honey has antiviral activity against RSV 
that is likely to be a result of a direct effect on the virus particle. Previous 
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studies suggest other roles that honey may play if used as a treatment for 
viral infections. As well as having antibacterial activity which would protect 
patients from secondary infections, honey has also been found to have some 
immunostimulatory effects (Tonks et al., 2003; Tonks et al., 2007), which 
would also augment the direct antiviral action and therefore contribute to 
the clearing of virus and healing of infection by the body’s own defences.  
 
The results obtained from this study present strong justification to test the 
effect of honey on the virus in more complex models.  
 
9.2 Recommendations for future work 
This study looked at several aspects of the antiviral activity of honey against 
RSV and has demonstrated its potential therapeutic benefits, however, 
further research is needed to increase knowledge in this area.  Future 
investigations should include, firstly, determining the mechanism of action 
of honey. This could be achieved by chromatographic separation of the 
honey into fractions, to test the antiviral activity of specific components. It 
would also be ideal to perform this test on a range of honeys with varying 
phytochemical profiles, as activity may be due to the presence of a number 
of compounds, not just one. Studies could also focus on determining the 
effects that honey may have on the expression of genes in cells which are 
involved in the antiviral response, such as NF-κB. Its role in the clearing of 
RSV infection by stimulating the body’s immune system should also be 
investigated as stimulation of B- and T-cell lymphocytes and activation of 
neutrophils by honey has been previously reported (Abuharfeil et al., 1999), 
as has the stimulation of monocytes in cell culture to release TNF-α and IL-1 
and IL-6 (Jones et al., 2000). These cytokines activate many facets of the 
immune response to infection (Benjamini et al., 1996). 
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Once the mechanism has been determined, studies may then move on to 
determining the efficacy of honey on more complex models including 
primary cell cultures. It will also be vital to investigate its effects in vivo using 
animal models as the internal lung environment is very complex and 
involves an array of biological processes, for example, mucus production, 
which may interfere with the intrapulmonary administration of honey.  
 
It is likely that honey may also have antiviral activity against a range of other 
RNA and respiratory viruses, however, these will need to be tested 
individually as honey does not appear to affect all viruses similarly, as 
demonstrated by the differences in the results observed from this study 
compared with previous studies. A wider range of honey types should also 
be tested for their antiviral activity, to determine which honeys have the 
greatest effect as this knowledge would be of benefit therapeutically. 
 
If clinical trials prove the effectiveness indicated by the results in the current 
study, it is possible that honey may be a better therapeutic option for the 
treatment of RSV infections compared with other treatments available today.   
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